A Phase 3 interventional study of Isatuximab IV and Isatuximab SC in Plasma Cell Myeloma Recurrent, sponsored by Sanofi. Active, not recruiting at 128 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.
Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 4th largest by enrollment, is one of 8 that started in 2022, is one of 9 in phase 3, reaches primary completion later than 1 of the 33 other live ones, and was the 33rd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18–75
Natalie Callander · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
By country, each count listing its studies:
isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 31 · Phase 3 11
First in 2013; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 531 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 55 across the 50 interventional studies. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 50 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
39 studies in Multiple Myeloma by Sanofi: 3 open now, 8 under way, 3 of them phase 3. Of 30 finished, 12 (40%) have results posted.
Among the 39 studies in Multiple Myeloma by Sanofi, this one has the largest enrollment of the 34 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 3, and was the 34th registered.
Sanofi’s Multiple Myeloma studies by the year they started, since 2002.
9 of the studies testing isatuximab in Multiple Myeloma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT06517017University of UtahUse of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma | 2026-11 |
| NCT06832865Massachusetts General HospitalELISA in Relapsed/Refractory MM | 2026-12-01 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 50 studies testing isatuximab in Multiple Myeloma, from their registry updates:
Among Sanofi’s 39 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who will receive at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants were randomized 1:1 into 1 of 2 study arms:
Arm SC: Isatuximab SC + Pd
Arm IV: Isatuximab IV + Pd
Participants are allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.
Two study arms are treated in 4-week cycles until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Isatuximab dose will administered SC weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days in duration. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days). Participants may receive other treatments as background treatment and/or rescue medication.
Drug: Isatuximab SC · Drug: Dexamethasone · Drug: Pomalidomide · Drug: Montelukast · Drug: Paracetamol / Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone
Isatuximab dose will be administered via IV infusion weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days). Participants may receive other treatments as background treatment and/or rescue medication.
Drug: Isatuximab IV · Drug: Dexamethasone · Drug: Pomalidomide · Drug: Montelukast · Drug: Paracetamol / Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone
Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
Also known as: SAR650984, SARCLISA®
Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
Also known as: SAR650984
Pharmaceutical form: Tablet; Route of administration: Oral
Pharmaceutical form: hard capsules; Route of administration: Oral
Also known as: Pomalyst or equivalent
Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
Drug page: Acetaminophen
Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
Overall Response Rate (ORR)
ORR by independent review committee (IRC) using 2016 international myeloma working group (IMWG) criteria:Percentage of participants with complete response (CR),stringent CR (sCR),very good partial response (VGPR) \& partial response (PR).CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas (STP),\<5% plasma cells in bone marrow (BM) aspirates \& a normal free light chain(FLC)ratio (0.26-1.65).sCR:CR plus no clonal cells in BM biopsy. VGPR:serum \& urine M-protein detectable by immunofixation, not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24hour(h);\>=90% decrease in sum of maximal perpendicular diameter (SPD) compared to baseline in STP;FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels.PR:\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h.In addition to above, if present at baseline,\>=50% reduction in size SPD of STPs also required.
Time frame: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State
Ctrough at steady state was the observed plasma concentration collected on pre-dose at Cycle 6 Day 1 (equivalent to prior to Cycle 6 Day 1) of isatuximab administration dose.
Time frame: Pre-dose at Cycle 6 Day 1
Very Good Partial Response or Better Rate
VGPR or better rate by IRC using 2016 IMWG criteria: Percentage of participants with sCR, CR, and VGPR. CR: negative immunofixation on serum and urine, disappearance of any STP, \<5% plasma cells in BM aspirates \& normal FLC ratio (0.26-1.65). sCR: CR plus no clonal cells in BM biopsy. VGPR: serum and urine M-protein detectable by immunofixation, not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24h;\>=90% decrease in SPD compared to baseline in STP; FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels. Percentages are rounded off to the tenth decimal place.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Ctrough of Isatuximab at 4 Weeks (CT4W)
The CT4W was the observed plasma concentrations collected on pre-dose at Cycle 2 Day 1 (equivalent to prior to Cycle 2 Day 1) of isatuximab administration dose.
Time frame: Pre-dose at Cycle 2 Day 1 (at 4 weeks)
Percentage of Participants With Infusion Reactions
Infusion reactions were graded using National Cancer Institute-Common Terminology Criteria for AE (NCI-CTCAE) version (v)5.0 criteria: Grade 1: mild transient reaction; infusion interruption not indicated; intervention not indicated. Grade 2: moderate reaction; therapy or infusion interruption indicated but responds promptly to symptomatic treatment; prophylactic medications indicated for \<=24 hours. Grade 3/4: severe or life-threatening reaction (Grade 3: prolonged \[not rapidly responsive to symptomatic medication and/or brief interruption of infusion\]; recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Grade 4: life-threatening consequences; urgent intervention indicated). Percentage of participants who observed AE of infusion reactions were collected through the electronic case report form (eCRF) as assessed by investigators. Percentages are rounded off to the tenth decimal place.
Time frame: From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months
Percentage of Participants Who Responded Very Satisfied and Satisfied to the 'Patient Experience and Satisfaction Questionnaire (PESQ-FU)': Satisfaction With Injection Method' (Item-8) at Cycle 5 Day 15
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'satisfaction with injection method' were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. The total percentage of participants who were very satisfied and satisfied with the injection method (item-8) at Cycle 5 Day 15 is reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 5 Day 15
Duration of Response (DOR)
DOR: Time from the date of first response to the date of first occurrence of progressive disease (PD) determined by IRC or death from any cause, whichever occurred first.DOR was determined only for participants who achieved a response (PR or better).If PD/death not observed, participant was censored at date of last valid disease assessment performed prior to initiating further anti-myeloma treatment or analysis cut-off date, whichever occurred first. As per IMWG criteria: PD: increase of \>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase\>=0.5 gram/deciliter\[g/dL\]),serum M-protein increase\>=1g/dL if lowest M-component \>=5g/dL, urine M-component (absolute increase \>=200mg/24h), appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in longest diameter of a previous lesion \>1 centimeter (cm) in short axis. PR: as defined in OM1.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Time to First Response (TT1R)
TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h. In addition to above, if present at baseline, \>=50% reduction in the size SPD of STPs was also required.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Time to Best Response (TTBR)
TTBR was defined as the time from randomization to the date of first occurrence of IRC determined best overall response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h. In addition to above, if present at baseline,\>=50% reduction in the size SPD of STPs was also required.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of first documentation of PD as determined by IRC or the date of death from any cause, whichever came first. Responses were determined according to IMWG criteria. PFS was censored at the date of the last valid disease assessment not showing PD performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever came first.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Overall Survival (OS)
OS was defined as the time from the date of randomization to death from any cause. Participants without death prior to the analysis cut-off date were censored at the last date the participant was known to be alive or the cut-off date, whichever was first.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Progression Free Survival 2 (PFS2)
PFS2 was defined as time from the date of randomization to the date of first documentation of PD (as assessed by Investigator) after initiation of further anti-myeloma treatment or death from any cause, whichever happened first. Same censoring rule applies as in the PFS endpoint.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An AE was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
Time frame: From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months
Isa-SC + Pd: Number of Participants With Injection Site Reactions (ISRs)
The ISRs are defined as AEs related to medication administration with onset typically within 24 hours from the start of the infusion and are graded using NCI-CTCAE v5.0 criteria: Grade 1: tenderness with or without associated symptoms (warmth, erythema, itching). Grade 2: pain; lipodystrophy; edema; phlebitis. Grade 3: ulceration or necrosis severe tissue damage operative intervention indicated. Grade 4: life-threatening consequences; urgent intervention indicated. ISRs were collected through the eCRF. Number of participants with at least 1 ISR is reported. ISRs were applicable only for the SC administration.
Time frame: From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months
Ctrough of Isatuximab
Plasma samples were collected at specified timepoints for the assessment of Ctrough.
Time frame: Pre-dose on Cycle 1 Days 8, 15 and 22, Cycles 2 to 5 Days 1 and 15, Cycles 6, 7, 8, 9, 12, 15, 18, 21, 24 and 27 Day 1
Isa-SC + Pd: Percentage of Successful Injections With Isatuximab Injector Device
Percentage of successful injections with investigational isatuximab injector device was defined as completion of administration per provided instructions for use with no use errors or technical issues divided by the total number of injections x 100. Delivery performance of the device was analyzed based on the successful injection rate in the Isa-SC + Pd arm as the investigational isatuximab injector device was used only for SC administration.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Isatuximab
A participant with treatment-emergent ADA was a participant with at least 1 treatment induced or treatment boosted ADA at any time during the treatment or follow-up observation period. Treatment-induced ADA was defined as ADAs developed de novo (seroconversion) following administration of the biotherapeutic (ie, formation of ADAs any time after the initial study medication administration in a participant without pre-existing ADAs). Treatment-boosted ADA was defined as pre-existing ADAs that were boosted to a higher level following administration of biotherapeutic (ie, any time after the initial study medication administration) the ADA titer was significantly higher than the baseline titer. Number of participants with treatment-emergent ADAs is presented.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Percentage of Participants With Response to 'Patient Expectation Questionnaire at Baseline (PEQ-BL)'
Percentage of participants who responded that they strongly agree or agree at baseline with expectations of pain, discomfort and side effects from the injection method, the injection method would save time, study medication may result in side effects and would be worth taking are reported. PEQ-BL consisted of 7 items. Percentage of participants who ever received medication through IV and/or SC administration are also reported. Percentages are rounded off to the tenth decimal place. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1)
Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Discomfort With Injection Method'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'discomfort with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any discomfort with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Pain With Injection Method'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'pain with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any pain with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Side Effects With Injection Method'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'side effects with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any side effects with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants Who Strongly Agreed and Agreed to 'PESQ-FU: Time Saving With Injection Method'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'time saving with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who strongly agreed and agreed that they experienced time saving with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants Who Responded Very Satisfied and Satisfied to 'PESQ-FU: Satisfaction With Injection Method'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'satisfaction with injection method' were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. Percentage of participants who were very satisfied and satisfied with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Side Effects With Study Medication'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'side effects with study medication' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any side effects with study medication are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants Who Strongly Agreed and Agreed to 'PESQ-FU: Study Medication Worth Taking'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'study medication worth taking' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who strongly agreed and agreed that the study medication was worth taking are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants Who Responded Very Satisfied and Satisfied to 'PESQ-FU: Satisfaction With Study Medication'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to satisfaction with study medication were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. Percentage of participants who were very satisfied and satisfied with the study medication are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants Who Responded Definitely Yes and Probably Yes to 'PESQ-FU: Recommendation of Study Medication'
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'recommendation of the study medication' were recorded as 'definitely yes, probably yes, unsure, probably not and definitely not' at specified timepoints. Percentage of participants who responded definitely yes and probably yes to the recommendation of study medication are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Percentage of Participants With Response to 'Patient Experience and Satisfaction End of Treatment Questionnaire (PESQ-EOT)'
The PESQ-EOT consisting of 17 items assessed participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation) and has been adapted based on qualitative interviews with oncology participants. In addition to the above, this questionnaire also includes additional items to assess whether participants received oncology medications in the past 2 years and if a participant received both IV and SC in the past 2 years, then participant preference on injection method (whether SC or IV). Percentage of participants with response to these additional items (received oncology medications in the past 2 years via IV/SC/both and if received both IV and SC; then the participant preference on injection method) are reported here. Percentages are rounded off to the tenth decimal place.
Time frame: EOT visit (up to DCO date: 29-Aug-2025) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 38 months)
Participant Responses to Patient's Assessment of Treatment (PAT) Questionnaire
The 4-item PAT is an internally developed non-disease specific and self-administered assessment which has been debriefed with oncology patients during qualitative interviews. It provided participant insights on the benefits and disadvantages of treatment. Benefits and disadvantages were respectively rated on a 0-10 scale wherein 0=none (not beneficial at all or no disadvantages at all) and 10=maximum (extremely beneficial or extremely disadvantageous). Disadvantages vs benefits were rated on a scale of -3 to 3 wherein -3=disadvantages significantly outweigh the benefits, 0=equal benefits and disadvantages and 3=benefits significantly outweigh the disadvantages. Mean of benefits, disadvantages and disadvantages vs benefits is presented here.
Time frame: EOT visit (up to DCO date: 29-Aug-2025) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 38 months)
Health Resource Utilization and Productivity Questionnaire (HRUPQ): Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Received Care
Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant received care in a clinic or hospital emergency room for any health issue including MM or due to MM and at-home care from a nurse or other health professional for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1)
HRUPQ: Baseline Healthcare Utilization: Number of Nights in the Past 6 Months a Participant Stayed in Hospital
Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of nights in the past 6 month a participant stayed in hospital for any health issue including MM or due to MM and stayed in intensive care unit (ICU) for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1)
HRUPQ: Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Consulted a Healthcare Professional (HCP)
Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant consulted (had seen or talked to) following healthcare professionals: general doctor or primary care clinician (PCC) who treats a variety of illnesses for any health issue including MM or related to MM, physical or occupational therapist for any health issue including MM or related to MM, mental health professional (e.g. psychiatrist, psychologist, psychiatric nurse) for any health issue including MM or related to MM, medical doctor or clinician who specializes in particular medical disease or issue (specialist) for any health issue including MM or related to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1)
Duration of Hospital Visits for Treatment Administration and Duration of Post-Treatment Monitoring Based on HRUPQ
Medical resource utilization was collected through HRUPQ. Participants were asked to indicate the duration of their hospital visit (from arrival to departure) and the duration of post-treatment monitoring based on their most recent isatuximab administration. The median duration across all visits (starting from Cycle 2) was calculated and reported here.
Time frame: From Cycle 2 Day 1 up to EOT visit (up to PCD: 06-Nov-2024) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)
Percentage of Participants Who Visited Healthcare Professional for Non-trial-related Health Issues Based on HRUPQ
Medical resource utilization was collected through HRUPQ. Percentage of participants with healthcare professional visit not required by clinical trial since last isatuximab administration was recorded. Percentages are rounded off to the tenth decimal place.
Time frame: Cycle 1 Days 8, 15 and 22, Cycle 2 Day 1, Cycles 3 to 29 Day 15 and EOT visit (up to PCD: 06-Nov-2024) (30 days after last drug administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)
Percentage of Participants Who Ever Retired During the Study Based on HRUPQ
Employment status was assessed via HRUPQ. Percentage of participants who ever retired during the study are reported. Percentages are rounded off to the tenth decimal place.
Time frame: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
Percentage of Participants Who Retired Early Due to MM Based on HRUPQ
Employment status was assessed via HRUPQ. Percentage of participants who retired early due to MM are reported. Percentages are rounded off to the tenth decimal place.
Time frame: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QoL)
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For GHS/QoL: overall health and quality of life were assessed, rated on a 7-point scale (1: very poor to 7: excellent). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for GHS/QoL and a positive change from baseline represents a healthy/better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Physical Functioning
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of physical functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Role Functioning
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of role functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Emotional Functioning
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of emotional functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Cognitive Functioning
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of cognitive functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Social Functioning
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of social functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Fatigue
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Nausea and Vomiting
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Pain
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Dyspnea
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Insomnia
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Appetite Loss
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Constipation
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Diarrhea
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-C30: Financial Difficulties
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of financial difficulties. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-Myeloma Module (MY20): Disease Symptoms
The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for disease symptoms and a positive change from baseline represents more symptoms, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-MY20: Side Effects of Treatment
The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for side effects of treatment and a positive change from baseline represents more side effects, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-MY20: Future Perspective
The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for future perspectives and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in EORTC QLQ-MY20: Body Image
The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for body image and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Change From Baseline in European Quality of Life Group Measure With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Visual Analogue Scale (VAS)
The EQ-5D-5L is a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and a VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The VAS records the respondent's self-rated health on a 20-cm vertical scale ranging from 0: the worst health you can imagine to 100: the best health you can imagine. Change from baseline in VAS is reported here. A higher score in VAS and positive change from baseline represents a better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 21 Day 15 and EOT visit (up to PCD: 06-Nov-2024) (30 days after last drug administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)
ORR Based on at Least 1 Chromosomal Abnormality
BM aspirate was collected for fluorescent in situ hybridization for analysis of del\[17p\], t\[4;14\], t\[14;16\]) and 1q21+. ORR was also evaluated based on IRC assessment by disease characteristics. ORR for participants with at least 1 chromosomal abnormality i.e. \[del(17p)\] or \[1q21+ and t(4;14) or t(14;16)\] is presented. Percentages are rounded off to the tenth decimal place.
Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
This study was conducted at 120 sites in 21 countries. A total of 637 participants were screened from 23-Jun-2022 to 13-May-2024, of which 106 were screen failures. Screen failures were mainly due to not meeting eligibility criteria.
| Milestone | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Started | 268 | 263 |
| Randomized and treated | 264 | 263 |
| Completed | 0 | 0 |
| Not completed | 268 | 263 |
| Withdrew: Death | 73 | 77 |
| Withdrew: Withdrawal by subject | 13 | 4 |
| Withdrew: Ongoing at the time of dco | 182 | 182 |
ORR by independent review committee (IRC) using 2016 international myeloma working group (IMWG) criteria:Percentage of participants with complete response (CR),stringent CR (sCR),very good partial response (VGPR) \& partial response (PR).CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas (STP),\<5% plasma cells in bone marrow (BM) aspirates \& a normal free light chain(FLC)ratio (0.26-1.65).sCR:CR plus no clonal cells in BM biopsy. VGPR:serum \& urine M-protein detectable by immunofixation, not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24hour(h);\>=90% decrease in sum of maximal perpendicular diameter (SPD) compared to baseline in STP;FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels.PR:\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h.In addition to above, if present at baseline,\>=50% reduction in size SPD of STPs also required.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Overall Response Rate (ORR) | 70.5 | 71.1 |
Ctrough at steady state was the observed plasma concentration collected on pre-dose at Cycle 6 Day 1 (equivalent to prior to Cycle 6 Day 1) of isatuximab administration dose.
| microgram/milliliter (mcg/mL) | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State | 340 ± 169 | 499 ± 259 |
VGPR or better rate by IRC using 2016 IMWG criteria: Percentage of participants with sCR, CR, and VGPR. CR: negative immunofixation on serum and urine, disappearance of any STP, \<5% plasma cells in BM aspirates \& normal FLC ratio (0.26-1.65). sCR: CR plus no clonal cells in BM biopsy. VGPR: serum and urine M-protein detectable by immunofixation, not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24h;\>=90% decrease in SPD compared to baseline in STP; FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Very Good Partial Response or Better Rate | 53.0 | 50.2 |
The CT4W was the observed plasma concentrations collected on pre-dose at Cycle 2 Day 1 (equivalent to prior to Cycle 2 Day 1) of isatuximab administration dose.
| mcg/mL | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Ctrough of Isatuximab at 4 Weeks (CT4W) | 302 ± 117 | 421 ± 215 |
Infusion reactions were graded using National Cancer Institute-Common Terminology Criteria for AE (NCI-CTCAE) version (v)5.0 criteria: Grade 1: mild transient reaction; infusion interruption not indicated; intervention not indicated. Grade 2: moderate reaction; therapy or infusion interruption indicated but responds promptly to symptomatic treatment; prophylactic medications indicated for \<=24 hours. Grade 3/4: severe or life-threatening reaction (Grade 3: prolonged \[not rapidly responsive to symptomatic medication and/or brief interruption of infusion\]; recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Grade 4: life-threatening consequences; urgent intervention indicated). Percentage of participants who observed AE of infusion reactions were collected through the electronic case report form (eCRF) as assessed by investigators. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Percentage of Participants With Infusion Reactions | 25.0 (19.89 to 30.68) | 1.9 (0.62 to 4.38) |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'satisfaction with injection method' were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. The total percentage of participants who were very satisfied and satisfied with the injection method (item-8) at Cycle 5 Day 15 is reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Percentage of Participants Who Responded Very Satisfied and Satisfied to the 'Patient Experience and Satisfaction Questionnaire (PESQ-FU)': Satisfaction With Injection Method' (Item-8) at Cycle 5 Day 15 | 54.1 | 71.1 |
DOR: Time from the date of first response to the date of first occurrence of progressive disease (PD) determined by IRC or death from any cause, whichever occurred first.DOR was determined only for participants who achieved a response (PR or better).If PD/death not observed, participant was censored at date of last valid disease assessment performed prior to initiating further anti-myeloma treatment or analysis cut-off date, whichever occurred first. As per IMWG criteria: PD: increase of \>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase\>=0.5 gram/deciliter\[g/dL\]),serum M-protein increase\>=1g/dL if lowest M-component \>=5g/dL, urine M-component (absolute increase \>=200mg/24h), appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in longest diameter of a previous lesion \>1 centimeter (cm) in short axis. PR: as defined in OM1.
| months | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Duration of Response (DOR) | 29.04 (25.791 to NA) | NA (22.177 to NA) |
TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h. In addition to above, if present at baseline, \>=50% reduction in the size SPD of STPs was also required.
| months | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Time to First Response (TT1R) | 1.87 (1.183 to 1.938) | 2.04 (1.906 to 2.793) |
TTBR was defined as the time from randomization to the date of first occurrence of IRC determined best overall response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h. In addition to above, if present at baseline,\>=50% reduction in the size SPD of STPs was also required.
| months | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Time to Best Response (TTBR) | 5.59 (4.698 to 6.439) | 5.78 (5.322 to 6.669) |
PFS was defined as the time from the date of randomization to the date of first documentation of PD as determined by IRC or the date of death from any cause, whichever came first. Responses were determined according to IMWG criteria. PFS was censored at the date of the last valid disease assessment not showing PD performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever came first.
| months | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Progression-free Survival (PFS) | 26.91 (15.934 to NA) | 20.34 (16.986 to 25.561) |
OS was defined as the time from the date of randomization to death from any cause. Participants without death prior to the analysis cut-off date were censored at the last date the participant was known to be alive or the cut-off date, whichever was first.
| months | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
PFS2 was defined as time from the date of randomization to the date of first documentation of PD (as assessed by Investigator) after initiation of further anti-myeloma treatment or death from any cause, whichever happened first. Same censoring rule applies as in the PFS endpoint.
| months | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Progression Free Survival 2 (PFS2) | NA (24.608 to NA) | NA (24.082 to NA) |
An AE was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
| Participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| TEAEs | 263 | 258 |
| TESAEs | 152 | 160 |
The ISRs are defined as AEs related to medication administration with onset typically within 24 hours from the start of the infusion and are graded using NCI-CTCAE v5.0 criteria: Grade 1: tenderness with or without associated symptoms (warmth, erythema, itching). Grade 2: pain; lipodystrophy; edema; phlebitis. Grade 3: ulceration or necrosis severe tissue damage operative intervention indicated. Grade 4: life-threatening consequences; urgent intervention indicated. ISRs were collected through the eCRF. Number of participants with at least 1 ISR is reported. ISRs were applicable only for the SC administration.
| Participants | Isa-SC + Pd |
|---|---|
| Isa-SC + Pd: Number of Participants With Injection Site Reactions (ISRs) | 12 |
Plasma samples were collected at specified timepoints for the assessment of Ctrough.
| mcg/mL | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8 | 92 ± 47 | 129 ± 66 |
| Cycle 1 Day 15 | 171 ± 84 | 249 ± 115 |
| Cycle 1 Day 22 | 227 ± 99 | 321 ± 144 |
| Cycle 2 Day 1 | 293 ± 117 | 407 ± 211 |
| Cycle 2 Day 15 | 243 ± 130 | 363 ± 228 |
| Cycle 3 Day 1 | 268 ± 133 | 381 ± 192 |
| Cycle 3 Day 15 | 256 ± 138 | 392 ± 245 |
| Cycle 4 Day 1 | 277 ± 151 | 477 ± 424 |
| Cycle 4 Day 15 | 285 ± 139 | 452 ± 400 |
| Cycle 5 Day 1 | 366 ± 568 | 470 ± 264 |
| Cycle 5 Day 15 | 306 ± 168 | 463 ± 275 |
| Cycle 6 Day 1 | 330 ± 165 | 491 ± 256 |
| Cycle 7 Day 1 | 339 ± 189 | 523 ± 336 |
| Cycle 8 Day 1 | 348 ± 172 | 569 ± 336 |
| Cycle 9 Day 1 | 365 ± 193 | 598 ± 369 |
| Cycle 12 Day 1 | 380 ± 214 | 593 ± 404 |
| Cycle 15 Day 1 | 354 ± 158 | 651 ± 361 |
| Cycle 18 Day 1 | 367 ± 140 | 645 ± 343 |
| Cycle 21 Day 1 | 388 ± 174 | 668 ± 213 |
| Cycle 24 Day 1 | 525 ± 455 | 651 ± 424 |
| Cycle 27 Day 1 | — | 566 ± 200 |
Percentage of successful injections with investigational isatuximab injector device was defined as completion of administration per provided instructions for use with no use errors or technical issues divided by the total number of injections x 100. Delivery performance of the device was analyzed based on the successful injection rate in the Isa-SC + Pd arm as the investigational isatuximab injector device was used only for SC administration.
| percentage of successful injections | Isa-SC + Pd |
|---|---|
| Isa-SC + Pd: Percentage of Successful Injections With Isatuximab Injector Device | 99.0 |
A participant with treatment-emergent ADA was a participant with at least 1 treatment induced or treatment boosted ADA at any time during the treatment or follow-up observation period. Treatment-induced ADA was defined as ADAs developed de novo (seroconversion) following administration of the biotherapeutic (ie, formation of ADAs any time after the initial study medication administration in a participant without pre-existing ADAs). Treatment-boosted ADA was defined as pre-existing ADAs that were boosted to a higher level following administration of biotherapeutic (ie, any time after the initial study medication administration) the ADA titer was significantly higher than the baseline titer. Number of participants with treatment-emergent ADAs is presented.
| Participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Isatuximab | 29 | 18 |
Percentage of participants who responded that they strongly agree or agree at baseline with expectations of pain, discomfort and side effects from the injection method, the injection method would save time, study medication may result in side effects and would be worth taking are reported. PEQ-BL consisted of 7 items. Percentage of participants who ever received medication through IV and/or SC administration are also reported. Percentages are rounded off to the tenth decimal place. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Injection method may be painful: strongly agree | 6.0 | 7.9 |
| Injection method may be painful: agree | 33.6 | 33.3 |
| Injection method may be uncomfortable: strongly agree | 11.1 | 9.6 |
| Injection method may be uncomfortable: agree | 37.8 | 25.9 |
| Injection method may result in side effects: strongly agree | 9.2 | 4.8 |
| Injection method may result in side effects: agree | 42.9 | 45.2 |
| Injection method will save me time: strongly agree | 9.2 | 21.1 |
| Injection method will save me time: agree | 31.8 | 51.8 |
| Study medication may result in side effects: strongly agree | 12.9 | 7.9 |
| Study medication may result in side effects: agree | 47.5 | 44.3 |
| Study medication would be worth taking: strongly agree | 26.7 | 26.8 |
| Study medication would be worth taking: agree | 47.0 | 47.8 |
| Ever received medication through IV | 74.2 | 62.3 |
| Ever received medication through SC | 48.8 | 61.4 |
| Neither received medication ever via IV or SC | 9.2 | 6.1 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'discomfort with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any discomfort with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: disagree | 33.2 | 40.1 |
| Cycle 1 Day 8: strongly disagree | 14.7 | 36.5 |
| Cycle 1 Day 15: disagree | 39.0 | 43.2 |
| Cycle 1 Day 15: strongly disagree | 15.2 | 38.3 |
| Cycle 1 Day 22: disagree | 39.6 | 45.0 |
| Cycle 1 Day 22: strongly disagree | 13.2 | 32.5 |
| Cycle 2 Day 1: disagree | 41.2 | 48.9 |
| Cycle 2 Day 1: strongly disagree | 13.3 | 31.7 |
| Cycle 2 Day 15: disagree | 41.2 | 47.9 |
| Cycle 2 Day 15: strongly disagree | 14.5 | 34.1 |
| Cycle 3 Day 1: disagree | 38.5 | 44.9 |
| Cycle 3 Day 1: strongly disagree | 13.8 | 33.3 |
| Cycle 4 Day 1: disagree | 36.3 | 44.2 |
| Cycle 4 Day 1: strongly disagree | 16.5 | 37.7 |
| Cycle 5 Day 15: disagree | 38.7 | 46.6 |
| Cycle 5 Day 15: strongly disagree | 15.2 | 32.1 |
| Cycle 6 Day 15: disagree | 36.2 | 42.4 |
| Cycle 6 Day 15: strongly disagree | 13.8 | 40.7 |
| Cycle 7 Day 15: disagree | 33.5 | 42.7 |
| Cycle 7 Day 15: strongly disagree | 16.8 | 40.9 |
| Cycle 8 Day 15: disagree | 34.5 | 44.4 |
| Cycle 8 Day 15: strongly disagree | 18.8 | 39.5 |
| Cycle 9 Day 15: disagree | 33.5 | 41.7 |
| Cycle 9 Day 15: strongly disagree | 20.3 | 37.5 |
| Cycle 10 Day 15: disagree | 36.0 | 40.7 |
| Cycle 10 Day 15: strongly disagree | 19.3 | 46.0 |
| Cycle 11 Day 15: disagree | 32.0 | 39.0 |
| Cycle 11 Day 15: strongly disagree | 19.3 | 44.7 |
| Cycle 12 Day 15: disagree | 30.5 | 42.2 |
| Cycle 12 Day 15: strongly disagree | 21.4 | 42.2 |
| Cycle 13 Day 15: disagree | 33.6 | 46.3 |
| Cycle 13 Day 15: strongly disagree | 17.6 | 42.3 |
| Cycle 14 Day 15: disagree | 30.9 | 45.6 |
| Cycle 14 Day 15: strongly disagree | 20.3 | 40.0 |
| Cycle 15 Day 15: disagree | 28.9 | 36.5 |
| Cycle 15 Day 15: strongly disagree | 20.2 | 41.7 |
| Cycle 16 Day 15: disagree | 27.9 | 38.9 |
| Cycle 16 Day 15: strongly disagree | 20.2 | 47.2 |
| Cycle 17 Day 15: disagree | 29.8 | 41.1 |
| Cycle 17 Day 15: strongly disagree | 18.1 | 45.3 |
| Cycle 18 Day 15: disagree | 37.2 | 39.3 |
| Cycle 18 Day 15: strongly disagree | 12.8 | 47.6 |
| Cycle 19 Day 15: disagree | 37.0 | 36.6 |
| Cycle 19 Day 15: strongly disagree | 16.4 | 45.1 |
| Cycle 20 Day 15: disagree | 37.9 | 43.9 |
| Cycle 20 Day 15: strongly disagree | 19.0 | 45.6 |
| Cycle 21 Day 15: disagree | 38.2 | 40.4 |
| Cycle 21 Day 15: strongly disagree | 7.3 | 46.8 |
| Cycle 22 Day 15: disagree | 29.4 | 43.9 |
| Cycle 22 Day 15: strongly disagree | 11.8 | 51.2 |
| Cycle 23 Day 15: disagree | 32.5 | 36.1 |
| Cycle 23 Day 15: strongly disagree | 7.5 | 52.8 |
| Cycle 24 Day 15: disagree | 22.0 | 38.7 |
| Cycle 24 Day 15: strongly disagree | 17.1 | 48.4 |
| Cycle 25 Day 15: disagree | 20.0 | 46.2 |
| Cycle 25 Day 15: strongly disagree | 17.1 | 50.0 |
| Cycle 26 Day 15: disagree | 25.0 | 48.0 |
| Cycle 26 Day 15: strongly disagree | 14.3 | 52.0 |
| Cycle 27 Day 15: disagree | 21.7 | 40.0 |
| Cycle 27 Day 15: strongly disagree | 17.4 | 46.7 |
| Cycle 28 Day 15: disagree | 31.3 | 50.0 |
| Cycle 28 Day 15: strongly disagree | 25.0 | 50.0 |
| Cycle 29 Day 15: disagree | 25.0 | 53.8 |
| Cycle 29 Day 15: strongly disagree | 25.0 | 46.2 |
| Cycle 30 Day 15: disagree | 28.6 | 55.6 |
| Cycle 30 Day 15: strongly disagree | 28.6 | 44.4 |
| Cycle 31 Day 15: disagree | 55.6 | 50.0 |
| Cycle 31 Day 15: strongly disagree | 11.1 | 50.0 |
| Cycle 32 Day 15: disagree | 37.5 | 75.0 |
| Cycle 32 Day 15: strongly disagree | 12.5 | 25.0 |
| Cycle 33 Day 15: disagree | 50.0 | 50.0 |
| Cycle 33 Day 15: strongly disagree | 16.7 | 50.0 |
| Cycle 34 Day 15: disagree | 75.0 | 75.0 |
| Cycle 34 Day 15: strongly disagree | 0 | 25.0 |
| Cycle 35 Day 15: disagree | 75.0 | 100 |
| Cycle 35 Day 15: strongly disagree | 0 | 0 |
| Cycle 36 Day 15: disagree | 100 | 100 |
| Cycle 36 Day 15: strongly disagree | 0 | 0 |
| Cycle 37 Day 15: disagree | 100 | 100 |
| Cycle 37 Day 15: strongly disagree | 0 | 0 |
| Cycle 38 Day 15: disagree | 100 | 100 |
| Cycle 38 Day 15: strongly disagree | 0 | 0 |
| Cycle 39 Day 15: disagree | — | 100 |
| Cycle 39 Day 15: strongly disagree | — | 0 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'pain with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any pain with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: disagree | 44.7 | 42.8 |
| Cycle 1 Day 8: strongly disagree | 19.8 | 40.5 |
| Cycle 1 Day 15: disagree | 47.1 | 44.7 |
| Cycle 1 Day 15: strongly disagree | 19.5 | 40.3 |
| Cycle 1 Day 22: disagree | 43.4 | 45.9 |
| Cycle 1 Day 22: strongly disagree | 19.8 | 36.8 |
| Cycle 2 Day 1: disagree | 49.4 | 51.5 |
| Cycle 2 Day 1: strongly disagree | 17.2 | 35.2 |
| Cycle 2 Day 15: disagree | 47.5 | 50.2 |
| Cycle 2 Day 15: strongly disagree | 17.2 | 37.4 |
| Cycle 3 Day 1: disagree | 45.0 | 51.4 |
| Cycle 3 Day 1: strongly disagree | 17.0 | 36.1 |
| Cycle 4 Day 1: disagree | 43.4 | 46.5 |
| Cycle 4 Day 1: strongly disagree | 18.4 | 39.5 |
| Cycle 5 Day 15: disagree | 46.1 | 50.8 |
| Cycle 5 Day 15: strongly disagree | 17.2 | 38.3 |
| Cycle 6 Day 15: disagree | 44.8 | 48.3 |
| Cycle 6 Day 15: strongly disagree | 17.8 | 42.4 |
| Cycle 7 Day 15: disagree | 46.2 | 47.6 |
| Cycle 7 Day 15: strongly disagree | 19.7 | 42.1 |
| Cycle 8 Day 15: disagree | 38.8 | 46.3 |
| Cycle 8 Day 15: strongly disagree | 23.0 | 40.7 |
| Cycle 9 Day 15: disagree | 41.8 | 41.7 |
| Cycle 9 Day 15: strongly disagree | 25.3 | 44.4 |
| Cycle 10 Day 15: disagree | 42.0 | 42.7 |
| Cycle 10 Day 15: strongly disagree | 24.0 | 49.3 |
| Cycle 11 Day 15: disagree | 40.0 | 41.1 |
| Cycle 11 Day 15: strongly disagree | 22.0 | 48.9 |
| Cycle 12 Day 15: disagree | 43.5 | 43.7 |
| Cycle 12 Day 15: strongly disagree | 22.1 | 44.4 |
| Cycle 13 Day 15: disagree | 43.2 | 48.8 |
| Cycle 13 Day 15: strongly disagree | 19.2 | 42.3 |
| Cycle 14 Day 15: disagree | 38.2 | 42.4 |
| Cycle 14 Day 15: strongly disagree | 22.8 | 44.8 |
| Cycle 15 Day 15: disagree | 38.6 | 40.9 |
| Cycle 15 Day 15: strongly disagree | 21.9 | 45.2 |
| Cycle 16 Day 15: disagree | 35.6 | 41.7 |
| Cycle 16 Day 15: strongly disagree | 23.1 | 48.1 |
| Cycle 17 Day 15: disagree | 41.5 | 48.4 |
| Cycle 17 Day 15: strongly disagree | 20.2 | 42.1 |
| Cycle 18 Day 15: disagree | 47.7 | 41.7 |
| Cycle 18 Day 15: strongly disagree | 20.9 | 51.2 |
| Cycle 19 Day 15: disagree | 45.2 | 43.7 |
| Cycle 19 Day 15: strongly disagree | 16.4 | 46.5 |
| Cycle 20 Day 15: disagree | 44.8 | 45.6 |
| Cycle 20 Day 15: strongly disagree | 17.2 | 47.4 |
| Cycle 21 Day 15: disagree | 47.3 | 38.3 |
| Cycle 21 Day 15: strongly disagree | 10.9 | 53.2 |
| Cycle 22 Day 15: disagree | 45.1 | 46.3 |
| Cycle 22 Day 15: strongly disagree | 13.7 | 53.7 |
| Cycle 23 Day 15: disagree | 55.0 | 36.1 |
| Cycle 23 Day 15: strongly disagree | 12.5 | 58.3 |
| Cycle 24 Day 15: disagree | 34.1 | 25.8 |
| Cycle 24 Day 15: strongly disagree | 19.5 | 51.6 |
| Cycle 25 Day 15: disagree | 42.9 | 42.3 |
| Cycle 25 Day 15: strongly disagree | 22.9 | 50.0 |
| Cycle 26 Day 15: disagree | 32.1 | 48.0 |
| Cycle 26 Day 15: strongly disagree | 14.3 | 52.0 |
| Cycle 27 Day 15: disagree | 43.5 | 40.0 |
| Cycle 27 Day 15: strongly disagree | 17.4 | 46.7 |
| Cycle 28 Day 15: disagree | 37.5 | 42.9 |
| Cycle 28 Day 15: strongly disagree | 18.8 | 50.0 |
| Cycle 29 Day 15: disagree | 31.3 | 53.8 |
| Cycle 29 Day 15: strongly disagree | 31.3 | 46.2 |
| Cycle 30 Day 15: disagree | 28.6 | 55.6 |
| Cycle 30 Day 15: strongly disagree | 28.6 | 44.4 |
| Cycle 31 Day 15: disagree | 55.6 | 50.0 |
| Cycle 31 Day 15: strongly disagree | 11.1 | 50.0 |
| Cycle 32 Day 15: disagree | 37.5 | 75.0 |
| Cycle 32 Day 15: strongly disagree | 25.0 | 25.0 |
| Cycle 33 Day 15: disagree | 66.7 | 50.0 |
| Cycle 33 Day 15: strongly disagree | 16.7 | 50.0 |
| Cycle 34 Day 15: disagree | 75.0 | 75.0 |
| Cycle 34 Day 15: strongly disagree | 0 | 25.0 |
| Cycle 35 Day 15: disagree | 75.0 | 100.0 |
| Cycle 35 Day 15: strongly disagree | 0 | 0 |
| Cycle 36 Day 15: disagree | 100 | 100 |
| Cycle 36 Day 15: strongly disagree | 0 | 0 |
| Cycle 37 Day 15: disagree | 100 | 100 |
| Cycle 37 Day 15: strongly disagree | 0 | 0 |
| Cycle 38 Day 15: disagree | 100 | 100 |
| Cycle 38 Day 15: strongly disagree | 0 | 0 |
| Cycle 39 Day 15: disagree | — | 100 |
| Cycle 39 Day 15: strongly disagree | — | 0 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'side effects with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any side effects with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: disagree | 41.0 | 46.4 |
| Cycle 1 Day 8: strongly disagree | 18.0 | 27.9 |
| Cycle 1 Day 15: disagree | 41.0 | 45.6 |
| Cycle 1 Day 15: strongly disagree | 15.2 | 25.2 |
| Cycle 1 Day 22: disagree | 44.3 | 42.1 |
| Cycle 1 Day 22: strongly disagree | 12.7 | 23.4 |
| Cycle 2 Day 1: disagree | 46.4 | 51.1 |
| Cycle 2 Day 1: strongly disagree | 12.0 | 23.8 |
| Cycle 2 Day 15: disagree | 44.8 | 49.3 |
| Cycle 2 Day 15: strongly disagree | 12.2 | 25.6 |
| Cycle 3 Day 1: disagree | 43.1 | 47.7 |
| Cycle 3 Day 1: strongly disagree | 13.3 | 28.2 |
| Cycle 4 Day 1: disagree | 42.9 | 53.5 |
| Cycle 4 Day 1: strongly disagree | 11.8 | 26.0 |
| Cycle 5 Day 15: disagree | 44.1 | 48.2 |
| Cycle 5 Day 15: strongly disagree | 14.7 | 29.0 |
| Cycle 6 Day 15: disagree | 45.4 | 46.5 |
| Cycle 6 Day 15: strongly disagree | 13.2 | 32.6 |
| Cycle 7 Day 15: disagree | 43.4 | 50.0 |
| Cycle 7 Day 15: strongly disagree | 16.2 | 33.5 |
| Cycle 8 Day 15: disagree | 35.8 | 46.9 |
| Cycle 8 Day 15: strongly disagree | 21.8 | 32.7 |
| Cycle 9 Day 15: disagree | 35.4 | 43.8 |
| Cycle 9 Day 15: strongly disagree | 22.2 | 38.2 |
| Cycle 10 Day 15: disagree | 45.3 | 38.7 |
| Cycle 10 Day 15: strongly disagree | 19.3 | 44.0 |
| Cycle 11 Day 15: disagree | 38.0 | 39.0 |
| Cycle 11 Day 15: strongly disagree | 18.7 | 39.7 |
| Cycle 12 Day 15: disagree | 42.7 | 48.9 |
| Cycle 12 Day 15: strongly disagree | 16.8 | 34.1 |
| Cycle 13 Day 15: disagree | 41.6 | 46.3 |
| Cycle 13 Day 15: strongly disagree | 16.8 | 35.8 |
| Cycle 14 Day 15: disagree | 35.0 | 49.6 |
| Cycle 14 Day 15: strongly disagree | 17.9 | 34.4 |
| Cycle 15 Day 15: disagree | 37.7 | 41.7 |
| Cycle 15 Day 15: strongly disagree | 18.4 | 37.4 |
| Cycle 16 Day 15: disagree | 32.7 | 38.9 |
| Cycle 16 Day 15: strongly disagree | 20.2 | 38.9 |
| Cycle 17 Day 15: disagree | 40.4 | 43.2 |
| Cycle 17 Day 15: strongly disagree | 19.1 | 40.0 |
| Cycle 18 Day 15: disagree | 41.9 | 42.9 |
| Cycle 18 Day 15: strongly disagree | 15.1 | 40.5 |
| Cycle 19 Day 15: disagree | 41.1 | 40.8 |
| Cycle 19 Day 15: strongly disagree | 16.4 | 43.7 |
| Cycle 20 Day 15: disagree | 34.5 | 45.6 |
| Cycle 20 Day 15: strongly disagree | 24.1 | 40.4 |
| Cycle 21 Day 15: disagree | 47.3 | 31.9 |
| Cycle 21 Day 15: strongly disagree | 10.9 | 51.1 |
| Cycle 22 Day 15: disagree | 41.2 | 48.8 |
| Cycle 22 Day 15: strongly disagree | 19.6 | 41.5 |
| Cycle 23 Day 15: disagree | 45.0 | 41.7 |
| Cycle 23 Day 15: strongly disagree | 17.5 | 44.4 |
| Cycle 24 Day 15: disagree | 36.6 | 41.9 |
| Cycle 24 Day 15: strongly disagree | 22.0 | 38.7 |
| Cycle 25 Day 15: disagree | 37.1 | 42.3 |
| Cycle 25 Day 15: strongly disagree | 25.7 | 42.3 |
| Cycle 26 Day 15: disagree | 35.7 | 40.0 |
| Cycle 26 Day 15: strongly disagree | 32.1 | 48.0 |
| Cycle 27 Day 15: disagree | 39.1 | 26.7 |
| Cycle 27 Day 15: strongly disagree | 30.4 | 46.7 |
| Cycle 28 Day 15: disagree | 43.8 | 57.1 |
| Cycle 28 Day 15: strongly disagree | 31.3 | 35.7 |
| Cycle 29 Day 15: disagree | 43.8 | 38.5 |
| Cycle 29 Day 15: strongly disagree | 18.8 | 38.5 |
| Cycle 30 Day 15: disagree | 35.7 | 44.4 |
| Cycle 30 Day 15: strongly disagree | 42.9 | 44.4 |
| Cycle 31 Day 15: disagree | 44.4 | 33.3 |
| Cycle 31 Day 15: strongly disagree | 22.2 | 50.0 |
| Cycle 32 Day 15: disagree | 50.0 | 50.0 |
| Cycle 32 Day 15: strongly disagree | 12.5 | 25.0 |
| Cycle 33 Day 15: disagree | 33.3 | 33.3 |
| Cycle 33 Day 15: strongly disagree | 33.3 | 50.0 |
| Cycle 34 Day 15: disagree | 25.0 | 50.0 |
| Cycle 34 Day 15: strongly disagree | 25.0 | 25.0 |
| Cycle 35 Day 15: disagree | 25.0 | 100.0 |
| Cycle 35 Day 15: strongly disagree | 25.0 | 0 |
| Cycle 36 Day 15: disagree | 50.0 | 66.7 |
| Cycle 36 Day 15: strongly disagree | 50.0 | 0 |
| Cycle 37 Day 15: disagree | 100 | 100 |
| Cycle 37 Day 15: strongly disagree | 0 | 0 |
| Cycle 38 Day 15: disagree | 0 | 100 |
| Cycle 38 Day 15: strongly disagree | 100 | 0 |
| Cycle 39 Day 15: disagree | — | 0 |
| Cycle 39 Day 15: strongly disagree | — | 0 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'time saving with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who strongly agreed and agreed that they experienced time saving with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: strongly agree | 5.5 | 36.9 |
| Cycle 1 Day 8: agree | 20.7 | 37.4 |
| Cycle 1 Day 15: strongly agree | 3.3 | 42.2 |
| Cycle 1 Day 15: agree | 25.7 | 38.3 |
| Cycle 1 Day 22: strongly agree | 5.2 | 35.9 |
| Cycle 1 Day 22: agree | 22.2 | 45.9 |
| Cycle 2 Day 1: strongly agree | 5.6 | 34.8 |
| Cycle 2 Day 1: agree | 25.8 | 46.3 |
| Cycle 2 Day 15: strongly agree | 5.4 | 32.7 |
| Cycle 2 Day 15: agree | 28.1 | 48.8 |
| Cycle 3 Day 1: strongly agree | 3.7 | 38.4 |
| Cycle 3 Day 1: agree | 25.7 | 45.8 |
| Cycle 4 Day 1: strongly agree | 7.5 | 38.1 |
| Cycle 4 Day 1: agree | 22.6 | 43.3 |
| Cycle 5 Day 15: strongly agree | 9.3 | 39.4 |
| Cycle 5 Day 15: agree | 23.0 | 43.5 |
| Cycle 6 Day 15: strongly agree | 7.5 | 41.3 |
| Cycle 6 Day 15: agree | 28.7 | 39.5 |
| Cycle 7 Day 15: strongly agree | 6.9 | 41.5 |
| Cycle 7 Day 15: agree | 28.9 | 40.9 |
| Cycle 8 Day 15: strongly agree | 12.1 | 38.3 |
| Cycle 8 Day 15: agree | 21.8 | 44.4 |
| Cycle 9 Day 15: strongly agree | 8.9 | 45.1 |
| Cycle 9 Day 15: agree | 26.6 | 39.6 |
| Cycle 10 Day 15: strongly agree | 9.3 | 42.0 |
| Cycle 10 Day 15: agree | 22.0 | 38.0 |
| Cycle 11 Day 15: strongly agree | 7.3 | 46.1 |
| Cycle 11 Day 15: agree | 28.0 | 39.0 |
| Cycle 12 Day 15: strongly agree | 8.4 | 43.7 |
| Cycle 12 Day 15: agree | 25.2 | 41.5 |
| Cycle 13 Day 15: strongly agree | 8.8 | 43.1 |
| Cycle 13 Day 15: agree | 28.0 | 42.3 |
| Cycle 14 Day 15: strongly agree | 10.6 | 40.0 |
| Cycle 14 Day 15: agree | 20.3 | 42.4 |
| Cycle 15 Day 15: strongly agree | 11.4 | 47.0 |
| Cycle 15 Day 15: agree | 21.9 | 46.1 |
| Cycle 16 Day 15: strongly agree | 14.4 | 49.1 |
| Cycle 16 Day 15: agree | 23.1 | 36.1 |
| Cycle 17 Day 15: strongly agree | 11.7 | 52.6 |
| Cycle 17 Day 15: agree | 22.3 | 37.9 |
| Cycle 18 Day 15: strongly agree | 10.5 | 46.4 |
| Cycle 18 Day 15: agree | 30.2 | 45.2 |
| Cycle 19 Day 15: strongly agree | 12.3 | 46.5 |
| Cycle 19 Day 15: agree | 23.3 | 43.7 |
| Cycle 20 Day 15: strongly agree | 10.3 | 52.6 |
| Cycle 20 Day 15: agree | 20.7 | 35.1 |
| Cycle 21 Day 15: strongly agree | 3.6 | 61.7 |
| Cycle 21 Day 15: agree | 23.6 | 31.9 |
| Cycle 22 Day 15: strongly agree | 7.8 | 48.8 |
| Cycle 22 Day 15: agree | 29.4 | 41.5 |
| Cycle 23 Day 15: strongly agree | 7.5 | 44.4 |
| Cycle 23 Day 15: agree | 27.5 | 47.2 |
| Cycle 24 Day 15: strongly agree | 9.8 | 51.6 |
| Cycle 24 Day 15: agree | 29.3 | 41.9 |
| Cycle 25 Day 15: strongly agree | 20.0 | 46.2 |
| Cycle 25 Day 15: agree | 22.9 | 34.6 |
| Cycle 26 Day 15: strongly agree | 21.4 | 52.0 |
| Cycle 26 Day 15: agree | 21.4 | 32.0 |
| Cycle 27 Day 15: strongly agree | 17.4 | 53.3 |
| Cycle 27 Day 15: agree | 26.1 | 40.0 |
| Cycle 28 Day 15: strongly agree | 25.0 | 50.0 |
| Cycle 28 Day 15: agree | 31.3 | 28.6 |
| Cycle 29 Day 15: strongly agree | 25.0 | 46.2 |
| Cycle 29 Day 15: agree | 31.3 | 38.5 |
| Cycle 30 Day 15: strongly agree | 21.4 | 44.4 |
| Cycle 30 Day 15: agree | 42.9 | 44.4 |
| Cycle 31 Day 15: strongly agree | 22.2 | 50.0 |
| Cycle 31 Day 15: agree | 55.6 | 33.3 |
| Cycle 32 Day 15: strongly agree | 25.0 | 25.0 |
| Cycle 32 Day 15: agree | 50.0 | 50.0 |
| Cycle 33 Day 15: strongly agree | 16.7 | 33.3 |
| Cycle 33 Day 15: agree | 66.7 | 33.3 |
| Cycle 34 Day 15: strongly agree | 0 | 50.0 |
| Cycle 34 Day 15: agree | 100 | 25.0 |
| Cycle 35 Day 15: strongly agree | 0 | 33.3 |
| Cycle 35 Day 15: agree | 100 | 33.3 |
| Cycle 36 Day 15: strongly agree | 0 | 33.3 |
| Cycle 36 Day 15: agree | 100 | 33.3 |
| Cycle 37 Day 15: strongly agree | 0 | 50.0 |
| Cycle 37 Day 15: agree | 100 | 0 |
| Cycle 38 Day 15: strongly agree | 0 | 50.0 |
| Cycle 38 Day 15: agree | 100 | 0 |
| Cycle 39 Day 15: strongly agree | — | 0 |
| Cycle 39 Day 15: agree | — | 0 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'satisfaction with injection method' were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. Percentage of participants who were very satisfied and satisfied with the injection method are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: very satisfied | 12.9 | 35.6 |
| Cycle 1 Day 8: satisfied | 53.0 | 53.2 |
| Cycle 1 Day 15: very satisfied | 16.7 | 43.2 |
| Cycle 1 Day 15: satisfied | 51.4 | 47.1 |
| Cycle 1 Day 22: very satisfied | 9.9 | 36.4 |
| Cycle 1 Day 22: satisfied | 54.7 | 52.6 |
| Cycle 2 Day 1: very satisfied | 12.4 | 39.2 |
| Cycle 2 Day 1: satisfied | 52.4 | 48.9 |
| Cycle 2 Day 15: very satisfied | 14.9 | 40.3 |
| Cycle 2 Day 15: satisfied | 54.3 | 52.1 |
| Cycle 3 Day 1: very satisfied | 13.8 | 41.7 |
| Cycle 3 Day 1: satisfied | 57.3 | 48.1 |
| Cycle 4 Day 1: very satisfied | 14.2 | 43.3 |
| Cycle 4 Day 1: satisfied | 55.7 | 50.7 |
| Cycle 5 Day 15: very satisfied | 18.6 | 49.2 |
| Cycle 5 Day 15: satisfied | 52.0 | 47.7 |
| Cycle 6 Day 15: very satisfied | 15.5 | 45.9 |
| Cycle 6 Day 15: satisfied | 53.4 | 45.9 |
| Cycle 7 Day 15: very satisfied | 17.9 | 50.0 |
| Cycle 7 Day 15: satisfied | 53.8 | 46.3 |
| Cycle 8 Day 15: very satisfied | 20.0 | 45.1 |
| Cycle 8 Day 15: satisfied | 46.7 | 46.9 |
| Cycle 9 Day 15: very satisfied | 24.1 | 50.7 |
| Cycle 9 Day 15: satisfied | 47.5 | 45.1 |
| Cycle 10 Day 15: very satisfied | 21.3 | 53.3 |
| Cycle 10 Day 15: satisfied | 46.0 | 40.7 |
| Cycle 11 Day 15: very satisfied | 21.3 | 56.0 |
| Cycle 11 Day 15: satisfied | 46.7 | 39.0 |
| Cycle 12 Day 15: very satisfied | 20.6 | 55.6 |
| Cycle 12 Day 15: satisfied | 51.1 | 40.0 |
| Cycle 13 Day 15: very satisfied | 23.2 | 48.8 |
| Cycle 13 Day 15: satisfied | 50.4 | 47.2 |
| Cycle 14 Day 15: very satisfied | 23.6 | 51.2 |
| Cycle 14 Day 15: satisfied | 46.3 | 43.2 |
| Cycle 15 Day 15: very satisfied | 26.3 | 53.9 |
| Cycle 15 Day 15: satisfied | 48.2 | 41.7 |
| Cycle 16 Day 15: very satisfied | 24.0 | 58.3 |
| Cycle 16 Day 15: satisfied | 50.0 | 38.0 |
| Cycle 17 Day 15: very satisfied | 27.7 | 54.7 |
| Cycle 17 Day 15: satisfied | 47.9 | 41.1 |
| Cycle 18 Day 15: very satisfied | 30.2 | 47.6 |
| Cycle 18 Day 15: satisfied | 50.0 | 47.6 |
| Cycle 19 Day 15: very satisfied | 17.8 | 53.5 |
| Cycle 19 Day 15: satisfied | 56.2 | 40.8 |
| Cycle 20 Day 15: very satisfied | 20.7 | 56.1 |
| Cycle 20 Day 15: satisfied | 50.0 | 38.6 |
| Cycle 21 Day 15: very satisfied | 14.5 | 70.2 |
| Cycle 21 Day 15: satisfied | 49.1 | 29.8 |
| Cycle 22 Day 15: very satisfied | 19.6 | 53.7 |
| Cycle 22 Day 15: satisfied | 54.9 | 43.9 |
| Cycle 23 Day 15: very satisfied | 25.0 | 58.3 |
| Cycle 23 Day 15: satisfied | 55.0 | 41.7 |
| Cycle 24 Day 15: very satisfied | 22.0 | 54.8 |
| Cycle 24 Day 15: satisfied | 53.7 | 45.2 |
| Cycle 25 Day 15: very satisfied | 22.9 | 53.8 |
| Cycle 25 Day 15: satisfied | 54.3 | 42.3 |
| Cycle 26 Day 15: very satisfied | 21.4 | 56.0 |
| Cycle 26 Day 15: satisfied | 60.7 | 44.0 |
| Cycle 27 Day 15: very satisfied | 26.1 | 60.0 |
| Cycle 27 Day 15: satisfied | 60.9 | 33.3 |
| Cycle 28 Day 15: very satisfied | 37.5 | 64.3 |
| Cycle 28 Day 15: satisfied | 56.3 | 35.7 |
| Cycle 29 Day 15: very satisfied | 37.5 | 61.5 |
| Cycle 29 Day 15: satisfied | 50.0 | 38.5 |
| Cycle 30 Day 15: very satisfied | 28.6 | 55.6 |
| Cycle 30 Day 15: satisfied | 64.3 | 44.4 |
| Cycle 31 Day 15: very satisfied | 66.7 | 66.7 |
| Cycle 31 Day 15: satisfied | 22.2 | 33.3 |
| Cycle 32 Day 15: very satisfied | 37.5 | 50.0 |
| Cycle 32 Day 15: satisfied | 50.0 | 50.0 |
| Cycle 33 Day 15: very satisfied | 33.3 | 66.7 |
| Cycle 33 Day 15: satisfied | 66.7 | 33.3 |
| Cycle 34 Day 15: very satisfied | 25.0 | 50.0 |
| Cycle 34 Day 15: satisfied | 75.0 | 50.0 |
| Cycle 35 Day 15: very satisfied | 50.0 | 33.3 |
| Cycle 35 Day 15: satisfied | 50.0 | 66.7 |
| Cycle 36 Day 15: very satisfied | 0 | 33.3 |
| Cycle 36 Day 15: satisfied | 100 | 66.7 |
| Cycle 37 Day 15: very satisfied | 0 | 50.0 |
| Cycle 37 Day 15: satisfied | 100 | 50.0 |
| Cycle 38 Day 15: very satisfied | 0 | 50.0 |
| Cycle 38 Day 15: satisfied | 100 | 50.0 |
| Cycle 39 Day 15: very satisfied | — | 0 |
| Cycle 39 Day 15: satisfied | — | 100 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'side effects with study medication' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any side effects with study medication are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: disagree | 35.0 | 45.0 |
| Cycle 1 Day 8: strongly disagree | 16.1 | 24.8 |
| Cycle 1 Day 15: disagree | 38.6 | 38.3 |
| Cycle 1 Day 15: strongly disagree | 12.9 | 23.8 |
| Cycle 1 Day 22: disagree | 41.0 | 40.2 |
| Cycle 1 Day 22: strongly disagree | 9.4 | 20.1 |
| Cycle 2 Day 1: disagree | 38.2 | 47.1 |
| Cycle 2 Day 1: strongly disagree | 9.0 | 22.9 |
| Cycle 2 Day 15: disagree | 41.6 | 47.4 |
| Cycle 2 Day 15: strongly disagree | 10.4 | 20.4 |
| Cycle 3 Day 1: disagree | 40.8 | 40.7 |
| Cycle 3 Day 1: strongly disagree | 11.0 | 26.4 |
| Cycle 4 Day 1: disagree | 40.1 | 48.4 |
| Cycle 4 Day 1: strongly disagree | 11.3 | 23.7 |
| Cycle 5 Day 15: disagree | 39.7 | 45.6 |
| Cycle 5 Day 15: strongly disagree | 12.3 | 26.9 |
| Cycle 6 Day 15: disagree | 39.1 | 44.2 |
| Cycle 6 Day 15: strongly disagree | 13.8 | 28.5 |
| Cycle 7 Day 15: disagree | 38.2 | 44.5 |
| Cycle 7 Day 15: strongly disagree | 15.6 | 32.3 |
| Cycle 8 Day 15: disagree | 33.3 | 43.2 |
| Cycle 8 Day 15: strongly disagree | 18.2 | 30.2 |
| Cycle 9 Day 15: disagree | 31.0 | 43.1 |
| Cycle 9 Day 15: strongly disagree | 20.3 | 33.3 |
| Cycle 10 Day 15: disagree | 39.3 | 38.0 |
| Cycle 10 Day 15: strongly disagree | 18.7 | 39.3 |
| Cycle 11 Day 15: disagree | 38.0 | 36.2 |
| Cycle 11 Day 15: strongly disagree | 18.7 | 37.6 |
| Cycle 12 Day 15: disagree | 37.4 | 47.4 |
| Cycle 12 Day 15: strongly disagree | 15.3 | 30.4 |
| Cycle 13 Day 15: disagree | 36.8 | 40.7 |
| Cycle 13 Day 15: strongly disagree | 16.0 | 35.0 |
| Cycle 14 Day 15: disagree | 35.8 | 46.4 |
| Cycle 14 Day 15: strongly disagree | 16.3 | 31.2 |
| Cycle 15 Day 15: disagree | 35.1 | 37.4 |
| Cycle 15 Day 15: strongly disagree | 20.2 | 37.4 |
| Cycle 16 Day 15: disagree | 26.0 | 37.0 |
| Cycle 16 Day 15: strongly disagree | 20.2 | 37.0 |
| Cycle 17 Day 15: disagree | 34.0 | 40.0 |
| Cycle 17 Day 15: strongly disagree | 21.3 | 38.9 |
| Cycle 18 Day 15: disagree | 37.2 | 34.5 |
| Cycle 18 Day 15: strongly disagree | 19.8 | 41.7 |
| Cycle 19 Day 15: disagree | 28.8 | 36.6 |
| Cycle 19 Day 15: strongly disagree | 19.2 | 39.4 |
| Cycle 20 Day 15: disagree | 22.4 | 40.4 |
| Cycle 20 Day 15: strongly disagree | 24.1 | 36.8 |
| Cycle 21 Day 15: disagree | 40.0 | 38.3 |
| Cycle 21 Day 15: strongly disagree | 10.9 | 46.8 |
| Cycle 22 Day 15: disagree | 39.2 | 41.5 |
| Cycle 22 Day 15: strongly disagree | 17.6 | 43.9 |
| Cycle 23 Day 15: disagree | 37.5 | 36.1 |
| Cycle 23 Day 15: strongly disagree | 17.5 | 41.7 |
| Cycle 24 Day 15: disagree | 31.7 | 48.4 |
| Cycle 24 Day 15: strongly disagree | 19.5 | 35.5 |
| Cycle 25 Day 15: disagree | 31.4 | 38.5 |
| Cycle 25 Day 15: strongly disagree | 25.7 | 42.3 |
| Cycle 26 Day 15: disagree | 28.6 | 44.0 |
| Cycle 26 Day 15: strongly disagree | 32.1 | 40.0 |
| Cycle 27 Day 15: disagree | 30.4 | 26.7 |
| Cycle 27 Day 15: strongly disagree | 30.4 | 46.7 |
| Cycle 28 Day 15: disagree | 31.3 | 42.9 |
| Cycle 28 Day 15: strongly disagree | 37.5 | 42.9 |
| Cycle 29 Day 15: disagree | 50.0 | 38.5 |
| Cycle 29 Day 15: strongly disagree | 18.8 | 46.2 |
| Cycle 30 Day 15: disagree | 35.7 | 44.4 |
| Cycle 30 Day 15: strongly disagree | 42.9 | 44.4 |
| Cycle 31 Day 15: disagree | 55.6 | 33.3 |
| Cycle 31 Day 15: strongly disagree | 22.2 | 33.3 |
| Cycle 32 Day 15: disagree | 37.5 | 25.0 |
| Cycle 32 Day 15: strongly disagree | 12.5 | 25.0 |
| Cycle 33 Day 15: disagree | 33.3 | 16.7 |
| Cycle 33 Day 15: strongly disagree | 33.3 | 50.0 |
| Cycle 34 Day 15: disagree | 25.0 | 50.0 |
| Cycle 34 Day 15: strongly disagree | 25.0 | 25.0 |
| Cycle 35 Day 15: disagree | 25.0 | 100 |
| Cycle 35 Day 15: strongly disagree | 25.0 | 0 |
| Cycle 36 Day 15: disagree | 50.0 | 33.3 |
| Cycle 36 Day 15: strongly disagree | 50.0 | 0 |
| Cycle 37 Day 15: disagree | 50.0 | 50.0 |
| Cycle 37 Day 15: strongly disagree | 50.0 | 0 |
| Cycle 38 Day 15: disagree | 0 | 100 |
| Cycle 38 Day 15: strongly disagree | 100 | 0 |
| Cycle 39 Day 15: disagree | — | 0 |
| Cycle 39 Day 15: strongly disagree | — | 0 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'study medication worth taking' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who strongly agreed and agreed that the study medication was worth taking are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: strongly agree | 18.0 | 33.8 |
| Cycle 1 Day 8: agree | 48.4 | 42.3 |
| Cycle 1 Day 15: strongly agree | 19.5 | 32.0 |
| Cycle 1 Day 15: agree | 51.9 | 49.5 |
| Cycle 1 Day 22: strongly agree | 20.8 | 30.6 |
| Cycle 1 Day 22: agree | 45.8 | 46.9 |
| Cycle 2 Day 1: strongly agree | 21.0 | 34.4 |
| Cycle 2 Day 1: agree | 48.9 | 46.7 |
| Cycle 2 Day 15: strongly agree | 21.7 | 31.8 |
| Cycle 2 Day 15: agree | 50.2 | 51.2 |
| Cycle 3 Day 1: strongly agree | 20.6 | 41.7 |
| Cycle 3 Day 1: agree | 52.8 | 46.8 |
| Cycle 4 Day 1: strongly agree | 23.1 | 39.5 |
| Cycle 4 Day 1: agree | 54.7 | 47.0 |
| Cycle 5 Day 15: strongly agree | 25.5 | 43.5 |
| Cycle 5 Day 15: agree | 49.5 | 49.7 |
| Cycle 6 Day 15: strongly agree | 25.9 | 41.9 |
| Cycle 6 Day 15: agree | 50.0 | 48.3 |
| Cycle 7 Day 15: strongly agree | 27.7 | 44.5 |
| Cycle 7 Day 15: agree | 52.6 | 45.7 |
| Cycle 8 Day 15: strongly agree | 28.5 | 42.0 |
| Cycle 8 Day 15: agree | 47.3 | 50.0 |
| Cycle 9 Day 15: strongly agree | 33.5 | 43.1 |
| Cycle 9 Day 15: agree | 45.6 | 47.2 |
| Cycle 10 Day 15: strongly agree | 30.0 | 45.3 |
| Cycle 10 Day 15: agree | 45.3 | 46.7 |
| Cycle 11 Day 15: strongly agree | 30.0 | 49.6 |
| Cycle 11 Day 15: agree | 48.7 | 41.1 |
| Cycle 12 Day 15: strongly agree | 27.5 | 48.9 |
| Cycle 12 Day 15: agree | 51.9 | 45.2 |
| Cycle 13 Day 15: strongly agree | 34.4 | 41.5 |
| Cycle 13 Day 15: agree | 47.2 | 52.0 |
| Cycle 14 Day 15: strongly agree | 35.8 | 40.0 |
| Cycle 14 Day 15: agree | 44.7 | 51.2 |
| Cycle 15 Day 15: strongly agree | 32.5 | 47.8 |
| Cycle 15 Day 15: agree | 43.9 | 47.8 |
| Cycle 16 Day 15: strongly agree | 39.4 | 49.1 |
| Cycle 16 Day 15: agree | 45.2 | 45.4 |
| Cycle 17 Day 15: strongly agree | 39.4 | 49.5 |
| Cycle 17 Day 15: agree | 40.4 | 45.3 |
| Cycle 18 Day 15: strongly agree | 32.6 | 47.6 |
| Cycle 18 Day 15: agree | 51.2 | 44.0 |
| Cycle 19 Day 15: strongly agree | 31.5 | 49.3 |
| Cycle 19 Day 15: agree | 49.3 | 40.8 |
| Cycle 20 Day 15: strongly agree | 36.2 | 54.4 |
| Cycle 20 Day 15: agree | 41.4 | 40.4 |
| Cycle 21 Day 15: strongly agree | 23.6 | 61.7 |
| Cycle 21 Day 15: agree | 58.2 | 36.2 |
| Cycle 22 Day 15: strongly agree | 31.4 | 51.2 |
| Cycle 22 Day 15: agree | 49.0 | 48.8 |
| Cycle 23 Day 15: strongly agree | 27.5 | 55.6 |
| Cycle 23 Day 15: agree | 52.5 | 44.4 |
| Cycle 24 Day 15: strongly agree | 41.5 | 51.6 |
| Cycle 24 Day 15: agree | 46.3 | 48.4 |
| Cycle 25 Day 15: strongly agree | 34.3 | 50.0 |
| Cycle 25 Day 15: agree | 54.3 | 50.0 |
| Cycle 26 Day 15: strongly agree | 46.4 | 60.0 |
| Cycle 26 Day 15: agree | 46.4 | 40.0 |
| Cycle 27 Day 15: strongly agree | 52.2 | 53.3 |
| Cycle 27 Day 15: agree | 34.8 | 46.7 |
| Cycle 28 Day 15: strongly agree | 50.0 | 57.1 |
| Cycle 28 Day 15: agree | 37.5 | 35.7 |
| Cycle 29 Day 15: strongly agree | 37.5 | 53.8 |
| Cycle 29 Day 15: agree | 56.3 | 46.2 |
| Cycle 30 Day 15: strongly agree | 71.4 | 66.7 |
| Cycle 30 Day 15: agree | 21.4 | 33.3 |
| Cycle 31 Day 15: strongly agree | 77.8 | 66.7 |
| Cycle 31 Day 15: agree | 11.1 | 33.3 |
| Cycle 32 Day 15: strongly agree | 75.0 | 75.0 |
| Cycle 32 Day 15: agree | 12.5 | 25.0 |
| Cycle 33 Day 15: strongly agree | 50.0 | 50.0 |
| Cycle 33 Day 15: agree | 50.0 | 50.0 |
| Cycle 34 Day 15: strongly agree | 50.0 | 75.0 |
| Cycle 34 Day 15: agree | 50.0 | 25.0 |
| Cycle 35 Day 15: strongly agree | 25.0 | 33.3 |
| Cycle 35 Day 15: agree | 75.0 | 66.7 |
| Cycle 36 Day 15: strongly agree | 0 | 33.3 |
| Cycle 36 Day 15: agree | 100 | 66.7 |
| Cycle 37 Day 15: strongly agree | 50.0 | 50.0 |
| Cycle 37 Day 15: agree | 50.0 | 50.0 |
| Cycle 38 Day 15: strongly agree | 100 | 50.0 |
| Cycle 38 Day 15: agree | 0 | 50.0 |
| Cycle 39 Day 15: strongly agree | — | 0 |
| Cycle 39 Day 15: agree | — | 100 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to satisfaction with study medication were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. Percentage of participants who were very satisfied and satisfied with the study medication are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: very satisfied | 17.1 | 29.3 |
| Cycle 1 Day 8: satisfied | 55.8 | 50.9 |
| Cycle 1 Day 15: very satisfied | 21.0 | 30.6 |
| Cycle 1 Day 15: satisfied | 48.1 | 48.1 |
| Cycle 1 Day 22: very satisfied | 16.0 | 30.1 |
| Cycle 1 Day 22: satisfied | 58.0 | 48.8 |
| Cycle 2 Day 1: very satisfied | 18.9 | 31.3 |
| Cycle 2 Day 1: satisfied | 53.6 | 50.2 |
| Cycle 2 Day 15: very satisfied | 20.8 | 30.3 |
| Cycle 2 Day 15: satisfied | 57.0 | 52.6 |
| Cycle 3 Day 1: very satisfied | 19.3 | 38.0 |
| Cycle 3 Day 1: satisfied | 61.5 | 49.5 |
| Cycle 4 Day 1: very satisfied | 21.2 | 37.7 |
| Cycle 4 Day 1: satisfied | 59.9 | 50.2 |
| Cycle 5 Day 15: very satisfied | 27.5 | 46.1 |
| Cycle 5 Day 15: satisfied | 54.9 | 46.1 |
| Cycle 6 Day 15: very satisfied | 27.0 | 41.9 |
| Cycle 6 Day 15: satisfied | 55.7 | 45.3 |
| Cycle 7 Day 15: very satisfied | 32.9 | 45.7 |
| Cycle 7 Day 15: satisfied | 49.1 | 48.8 |
| Cycle 8 Day 15: very satisfied | 33.3 | 44.4 |
| Cycle 8 Day 15: satisfied | 49.7 | 47.5 |
| Cycle 9 Day 15: very satisfied | 39.9 | 48.6 |
| Cycle 9 Day 15: satisfied | 45.6 | 45.1 |
| Cycle 10 Day 15: very satisfied | 34.7 | 47.3 |
| Cycle 10 Day 15: satisfied | 48.7 | 44.0 |
| Cycle 11 Day 15: very satisfied | 33.3 | 48.9 |
| Cycle 11 Day 15: satisfied | 52.0 | 44.0 |
| Cycle 12 Day 15: very satisfied | 32.8 | 49.6 |
| Cycle 12 Day 15: satisfied | 53.4 | 43.7 |
| Cycle 13 Day 15: very satisfied | 37.6 | 51.2 |
| Cycle 13 Day 15: satisfied | 48.8 | 43.1 |
| Cycle 14 Day 15: very satisfied | 39.0 | 44.0 |
| Cycle 14 Day 15: satisfied | 49.6 | 47.2 |
| Cycle 15 Day 15: very satisfied | 36.8 | 51.3 |
| Cycle 15 Day 15: satisfied | 48.2 | 44.3 |
| Cycle 16 Day 15: very satisfied | 45.2 | 53.7 |
| Cycle 16 Day 15: satisfied | 43.3 | 39.8 |
| Cycle 17 Day 15: very satisfied | 38.3 | 53.7 |
| Cycle 17 Day 15: satisfied | 45.7 | 42.1 |
| Cycle 18 Day 15: very satisfied | 39.5 | 53.6 |
| Cycle 18 Day 15: satisfied | 52.3 | 39.3 |
| Cycle 19 Day 15: very satisfied | 35.6 | 53.5 |
| Cycle 19 Day 15: satisfied | 50.7 | 39.4 |
| Cycle 20 Day 15: very satisfied | 41.4 | 49.1 |
| Cycle 20 Day 15: satisfied | 44.8 | 43.9 |
| Cycle 21 Day 15: very satisfied | 40.0 | 68.1 |
| Cycle 21 Day 15: satisfied | 47.3 | 27.7 |
| Cycle 22 Day 15: very satisfied | 37.3 | 48.8 |
| Cycle 22 Day 15: satisfied | 51.0 | 46.3 |
| Cycle 23 Day 15: very satisfied | 32.5 | 50.0 |
| Cycle 23 Day 15: satisfied | 52.5 | 50.0 |
| Cycle 24 Day 15: very satisfied | 41.5 | 48.4 |
| Cycle 24 Day 15: satisfied | 46.3 | 48.4 |
| Cycle 25 Day 15: very satisfied | 40.0 | 57.7 |
| Cycle 25 Day 15: satisfied | 45.7 | 42.3 |
| Cycle 26 Day 15: very satisfied | 46.4 | 64.0 |
| Cycle 26 Day 15: satisfied | 42.9 | 36.0 |
| Cycle 27 Day 15: very satisfied | 43.5 | 60.0 |
| Cycle 27 Day 15: satisfied | 47.8 | 33.3 |
| Cycle 28 Day 15: very satisfied | 50.0 | 64.3 |
| Cycle 28 Day 15: satisfied | 43.8 | 28.6 |
| Cycle 29 Day 15: very satisfied | 56.3 | 53.8 |
| Cycle 29 Day 15: satisfied | 37.5 | 46.2 |
| Cycle 30 Day 15: very satisfied | 50.0 | 66.7 |
| Cycle 30 Day 15: satisfied | 42.9 | 33.3 |
| Cycle 31 Day 15: very satisfied | 77.8 | 66.7 |
| Cycle 31 Day 15: satisfied | 11.1 | 33.3 |
| Cycle 32 Day 15: very satisfied | 75.0 | 75.0 |
| Cycle 32 Day 15: satisfied | 12.5 | 25.0 |
| Cycle 33 Day 15: very satisfied | 50.0 | 66.7 |
| Cycle 33 Day 15: satisfied | 50.0 | 33.3 |
| Cycle 34 Day 15: very satisfied | 50.0 | 50.0 |
| Cycle 34 Day 15: satisfied | 50.0 | 50.0 |
| Cycle 35 Day 15: very satisfied | 50.0 | 33.3 |
| Cycle 35 Day 15: satisfied | 50.0 | 66.7 |
| Cycle 36 Day 15: very satisfied | 50.0 | 33.3 |
| Cycle 36 Day 15: satisfied | 50.0 | 66.7 |
| Cycle 37 Day 15: very satisfied | 0 | 50.0 |
| Cycle 37 Day 15: satisfied | 100 | 50.0 |
| Cycle 38 Day 15: very satisfied | 100 | 50.0 |
| Cycle 38 Day 15: satisfied | 0 | 50.0 |
| Cycle 39 Day 15: very satisfied | — | 0 |
| Cycle 39 Day 15: satisfied | — | 100 |
The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'recommendation of the study medication' were recorded as 'definitely yes, probably yes, unsure, probably not and definitely not' at specified timepoints. Percentage of participants who responded definitely yes and probably yes to the recommendation of study medication are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8: definitely yes | 24.4 | 50.5 |
| Cycle 1 Day 8: probably yes | 43.3 | 34.7 |
| Cycle 1 Day 15: definitely yes | 30.0 | 46.1 |
| Cycle 1 Day 15: probably yes | 44.3 | 37.9 |
| Cycle 1 Day 22: definitely yes | 26.9 | 45.9 |
| Cycle 1 Day 22: probably yes | 46.7 | 39.7 |
| Cycle 2 Day 1: definitely yes | 25.8 | 49.8 |
| Cycle 2 Day 1: probably yes | 42.9 | 36.6 |
| Cycle 2 Day 15: definitely yes | 27.1 | 47.9 |
| Cycle 2 Day 15: probably yes | 46.6 | 38.9 |
| Cycle 3 Day 1: definitely yes | 28.4 | 53.2 |
| Cycle 3 Day 1: probably yes | 48.6 | 36.6 |
| Cycle 4 Day 1: definitely yes | 29.7 | 52.6 |
| Cycle 4 Day 1: probably yes | 50.0 | 38.6 |
| Cycle 5 Day 15: definitely yes | 33.8 | 59.6 |
| Cycle 5 Day 15: probably yes | 47.5 | 34.2 |
| Cycle 6 Day 15: definitely yes | 33.9 | 56.4 |
| Cycle 6 Day 15: probably yes | 46.0 | 39.0 |
| Cycle 7 Day 15: definitely yes | 32.9 | 59.8 |
| Cycle 7 Day 15: probably yes | 45.7 | 35.4 |
| Cycle 8 Day 15: definitely yes | 43.0 | 56.2 |
| Cycle 8 Day 15: probably yes | 35.8 | 37.7 |
| Cycle 9 Day 15: definitely yes | 39.9 | 59.7 |
| Cycle 9 Day 15: probably yes | 41.1 | 37.5 |
| Cycle 10 Day 15: definitely yes | 42.0 | 63.3 |
| Cycle 10 Day 15: probably yes | 40.0 | 30.7 |
| Cycle 11 Day 15: definitely yes | 41.3 | 63.1 |
| Cycle 11 Day 15: probably yes | 38.0 | 29.8 |
| Cycle 12 Day 15: definitely yes | 38.9 | 60.0 |
| Cycle 12 Day 15: probably yes | 35.9 | 34.1 |
| Cycle 13 Day 15: definitely yes | 40.0 | 61.8 |
| Cycle 13 Day 15: probably yes | 36.8 | 31.7 |
| Cycle 14 Day 15: definitely yes | 41.5 | 60.0 |
| Cycle 14 Day 15: probably yes | 35.0 | 32.0 |
| Cycle 15 Day 15: definitely yes | 45.6 | 58.3 |
| Cycle 15 Day 15: probably yes | 35.1 | 33.9 |
| Cycle 16 Day 15: definitely yes | 46.2 | 60.2 |
| Cycle 16 Day 15: probably yes | 37.5 | 32.4 |
| Cycle 17 Day 15: definitely yes | 51.1 | 54.7 |
| Cycle 17 Day 15: probably yes | 24.5 | 36.8 |
| Cycle 18 Day 15: definitely yes | 39.5 | 63.1 |
| Cycle 18 Day 15: probably yes | 40.7 | 29.8 |
| Cycle 19 Day 15: definitely yes | 35.6 | 60.6 |
| Cycle 19 Day 15: probably yes | 39.7 | 33.8 |
| Cycle 20 Day 15: definitely yes | 50.0 | 64.9 |
| Cycle 20 Day 15: probably yes | 25.9 | 29.8 |
| Cycle 21 Day 15: definitely yes | 38.2 | 70.2 |
| Cycle 21 Day 15: probably yes | 34.5 | 25.5 |
| Cycle 22 Day 15: definitely yes | 39.2 | 65.9 |
| Cycle 22 Day 15: probably yes | 37.3 | 26.8 |
| Cycle 23 Day 15: definitely yes | 47.5 | 69.4 |
| Cycle 23 Day 15: probably yes | 27.5 | 27.8 |
| Cycle 24 Day 15: definitely yes | 43.9 | 58.1 |
| Cycle 24 Day 15: probably yes | 31.7 | 38.7 |
| Cycle 25 Day 15: definitely yes | 48.6 | 69.2 |
| Cycle 25 Day 15: probably yes | 28.6 | 26.9 |
| Cycle 26 Day 15: definitely yes | 39.3 | 72.0 |
| Cycle 26 Day 15: probably yes | 46.4 | 24.0 |
| Cycle 27 Day 15: definitely yes | 39.1 | 60.0 |
| Cycle 27 Day 15: probably yes | 39.1 | 26.7 |
| Cycle 28 Day 15: definitely yes | 56.3 | 57.1 |
| Cycle 28 Day 15: probably yes | 31.3 | 28.6 |
| Cycle 29 Day 15: definitely yes | 56.3 | 61.5 |
| Cycle 29 Day 15: probably yes | 25.0 | 30.8 |
| Cycle 30 Day 15: definitely yes | 71.4 | 66.7 |
| Cycle 30 Day 15: probably yes | 7.1 | 22.2 |
| Cycle 31 Day 15: definitely yes | 77.8 | 66.7 |
| Cycle 31 Day 15: probably yes | 11.1 | 16.7 |
| Cycle 32 Day 15: definitely yes | 75.0 | 50.0 |
| Cycle 32 Day 15: probably yes | 12.5 | 25.0 |
| Cycle 33 Day 15: definitely yes | 66.7 | 50.0 |
| Cycle 33 Day 15: probably yes | 33.3 | 33.3 |
| Cycle 34 Day 15: definitely yes | 50.0 | 50.0 |
| Cycle 34 Day 15: probably yes | 50.0 | 25.0 |
| Cycle 35 Day 15: definitely yes | 50.0 | 33.3 |
| Cycle 35 Day 15: probably yes | 50.0 | 33.3 |
| Cycle 36 Day 15: definitely yes | 50.0 | 33.3 |
| Cycle 36 Day 15: probably yes | 50.0 | 33.3 |
| Cycle 37 Day 15: definitely yes | 50.0 | 50.0 |
| Cycle 37 Day 15: probably yes | 50.0 | 0 |
| Cycle 38 Day 15: definitely yes | 100 | 50.0 |
| Cycle 38 Day 15: probably yes | 0 | 0 |
| Cycle 39 Day 15: definitely yes | — | 0 |
| Cycle 39 Day 15: probably yes | — | 0 |
The PESQ-EOT consisting of 17 items assessed participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation) and has been adapted based on qualitative interviews with oncology participants. In addition to the above, this questionnaire also includes additional items to assess whether participants received oncology medications in the past 2 years and if a participant received both IV and SC in the past 2 years, then participant preference on injection method (whether SC or IV). Percentage of participants with response to these additional items (received oncology medications in the past 2 years via IV/SC/both and if received both IV and SC; then the participant preference on injection method) are reported here. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Received oncology medications in the past 2 years via IV only | 59.4 | 25.7 |
| Received oncology medications in the past 2 years via SC only | 9.4 | 31.9 |
| Received oncology medications in the past 2 years via both IV and SC | 13.2 | 18.6 |
| If received via both IV and SC: Preference for injection method: IV | 7.1 | 0 |
| If received via both IV and SC: Preference for injection method: SC | 57.1 | 90.5 |
| If received via both IV and SC: No preference for injection method | 35.7 | 9.5 |
The 4-item PAT is an internally developed non-disease specific and self-administered assessment which has been debriefed with oncology patients during qualitative interviews. It provided participant insights on the benefits and disadvantages of treatment. Benefits and disadvantages were respectively rated on a 0-10 scale wherein 0=none (not beneficial at all or no disadvantages at all) and 10=maximum (extremely beneficial or extremely disadvantageous). Disadvantages vs benefits were rated on a scale of -3 to 3 wherein -3=disadvantages significantly outweigh the benefits, 0=equal benefits and disadvantages and 3=benefits significantly outweigh the disadvantages. Mean of benefits, disadvantages and disadvantages vs benefits is presented here.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Benefits | 6.1 ± 2.4 | 6.6 ± 2.3 |
| Disadvantages | 4.0 ± 2.7 | 3.4 ± 2.6 |
| Disadvantages vs benefits | 0.7 ± 1.9 | 1.4 ± 1.8 |
Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant received care in a clinic or hospital emergency room for any health issue including MM or due to MM and at-home care from a nurse or other health professional for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| number of times received care | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| In a clinic or hospital emergency room for any health issue including MM | 3.6 ± 3.6 | 3.7 ± 4.1 |
| In a clinic or hospital emergency room due to MM | 4.4 ± 3.3 | 4.2 ± 4.2 |
| At-home from nurse or other health professional for any health issue including MM | 4.4 ± 5.4 | 3.8 ± 3.2 |
| At-home from nurse or other health professional due to MM | 4.7 ± 5.9 | 3.9 ± 3.6 |
Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of nights in the past 6 month a participant stayed in hospital for any health issue including MM or due to MM and stayed in intensive care unit (ICU) for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| number of nights | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Stayed in hospital for any health issue including MM | 7.2 ± 12.3 | 5.2 ± 9.0 |
| Stayed in hospital due to MM | 10.3 ± 20.2 | 6.5 ± 10.3 |
| Stayed in ICU for any health issue including MM | 5.0 ± 2.6 | 1.3 ± 0.5 |
| Stayed in ICU due to MM | — | 3.0 ± 2.0 |
Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant consulted (had seen or talked to) following healthcare professionals: general doctor or primary care clinician (PCC) who treats a variety of illnesses for any health issue including MM or related to MM, physical or occupational therapist for any health issue including MM or related to MM, mental health professional (e.g. psychiatrist, psychologist, psychiatric nurse) for any health issue including MM or related to MM, medical doctor or clinician who specializes in particular medical disease or issue (specialist) for any health issue including MM or related to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| number of times consulted a HCP | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| General doctor or PCC for any health issue including MM | 4.5 ± 3.9 | 4.9 ± 5.4 |
| General doctor or PCC for health issue related to MM | 4.5 ± 3.9 | 5.3 ± 7.6 |
| Physical or occupational therapist for any health issue including MM | 6.3 ± 5.3 | 6.7 ± 9.7 |
| Physical or occupational therapist for health issue related to MM | 6.2 ± 5.4 | 5.0 ± 6.4 |
| Mental health professional for any health issue including MM | 3.2 ± 3.0 | 5.2 ± 7.4 |
| Mental health professional for health issue related to MM | 3.3 ± 2.4 | 4.4 ± 7.8 |
| Medical doctor or clinician (specialist) for any health issue including MM | 4.2 ± 3.1 | 4.4 ± 3.3 |
| Medical doctor or clinician (specialist) for health issue related to MM | 4.5 ± 3.0 | 4.2 ± 2.4 |
Medical resource utilization was collected through HRUPQ. Participants were asked to indicate the duration of their hospital visit (from arrival to departure) and the duration of post-treatment monitoring based on their most recent isatuximab administration. The median duration across all visits (starting from Cycle 2) was calculated and reported here.
| minutes | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Duration of hospital visit | 240.00 (1.0 to 500.0) | 180.00 (1.0 to 600.0) |
| Duration of post-treatment monitoring | 30.00 (1.0 to 500.0) | 30.00 (1.0 to 500.0) |
Medical resource utilization was collected through HRUPQ. Percentage of participants with healthcare professional visit not required by clinical trial since last isatuximab administration was recorded. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 1 Day 8 | 11.4 | 14.9 |
| Cycle 1 Day 15 | 10.0 | 9.2 |
| Cycle 1 Day 22 | 11.7 | 9.8 |
| Cycle 2 Day 1 | 12.5 | 10.8 |
| Cycle 3 Day 15 | 13.2 | 11.5 |
| Cycle 4 Day 15 | 13.1 | 8.5 |
| Cycle 5 Day 15 | 8.9 | 7.3 |
| Cycle 6 Day 15 | 9.7 | 9.2 |
| Cycle 7 Day 15 | 13.2 | 9.2 |
| Cycle 8 Day 15 | 16.7 | 14.6 |
| Cycle 9 Day 15 | 11.6 | 14.1 |
| Cycle 10 Day 15 | 10.9 | 14.1 |
| Cycle 11 Day 15 | 13.0 | 10.4 |
| Cycle 12 Day 15 | 6.8 | 10.9 |
| Cycle 13 Day 15 | 16.9 | 12.3 |
| Cycle 14 Day 15 | 12.5 | 5.8 |
| Cycle 15 Day 15 | 18.8 | 12.5 |
| Cycle 16 Day 15 | 7.5 | 13.9 |
| Cycle 17 Day 15 | 15.2 | 16.7 |
| Cycle 18 Day 15 | 13.0 | 12.0 |
| Cycle 19 Day 15 | 8.3 | 13.6 |
| Cycle 20 Day 15 | 12.5 | 15.8 |
| Cycle 21 Day 15 | 25.0 | 0 |
| Cycle 22 Day 15 | 44.4 | 11.1 |
| Cycle 23 Day 15 | 0 | 22.2 |
| Cycle 24 Day 15 | 20.0 | 0 |
| Cycle 25 Day 15 | 0 | 25.0 |
| Cycle 26 Day 15 | 0 | 0 |
| Cycle 27 Day 15 | 0 | 0 |
| Cycle 28 Day 15 | — | 50.0 |
| Cycle 29 Day 15 | — | 0 |
| EOT visit | 25.0 | 17.1 |
Employment status was assessed via HRUPQ. Percentage of participants who ever retired during the study are reported. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Percentage of Participants Who Ever Retired During the Study Based on HRUPQ | 81.7 | 83.6 |
Employment status was assessed via HRUPQ. Percentage of participants who retired early due to MM are reported. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Percentage of Participants Who Retired Early Due to MM Based on HRUPQ | 32.0 | 37.3 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For GHS/QoL: overall health and quality of life were assessed, rated on a 7-point scale (1: very poor to 7: excellent). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for GHS/QoL and a positive change from baseline represents a healthy/better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -2.75 ± 18.66 | -1.50 ± 17.72 |
| Cycle 3 Day 15 | -0.56 ± 19.15 | -0.23 ± 18.05 |
| Cycle 4 Day 15 | -0.05 ± 19.16 | 1.41 ± 19.37 |
| Cycle 5 Day 15 | 0.65 ± 18.49 | 1.42 ± 20.67 |
| Cycle 6 Day 15 | 0.06 ± 18.40 | 3.17 ± 19.52 |
| Cycle 7 Day 15 | -0.23 ± 21.41 | 3.15 ± 20.62 |
| Cycle 8 Day 15 | 1.88 ± 16.65 | 0.43 ± 19.75 |
| Cycle 9 Day 15 | -0.19 ± 20.03 | 1.13 ± 20.32 |
| Cycle 10 Day 15 | 0.21 ± 18.83 | 3.05 ± 20.61 |
| Cycle 11 Day 15 | -1.03 ± 19.29 | 1.06 ± 20.34 |
| Cycle 12 Day 15 | -0.31 ± 18.91 | 2.65 ± 21.08 |
| Cycle 13 Day 15 | 0.89 ± 19.73 | 4.63 ± 18.57 |
| Cycle 14 Day 15 | 0.25 ± 19.69 | 1.43 ± 21.35 |
| Cycle 15 Day 15 | -0.61 ± 20.10 | 0.17 ± 20.62 |
| Cycle 16 Day 15 | 1.18 ± 17.16 | 2.51 ± 21.13 |
| Cycle 17 Day 15 | -0.32 ± 17.97 | 1.19 ± 20.46 |
| Cycle 18 Day 15 | -1.35 ± 19.88 | 0.60 ± 19.78 |
| Cycle 19 Day 15 | -1.88 ± 19.05 | 0.14 ± 22.24 |
| Cycle 20 Day 15 | -0.63 ± 17.67 | -0.54 ± 21.33 |
| Cycle 21 Day 15 | 0.33 ± 19.00 | 3.07 ± 21.17 |
| Cycle 22 Day 15 | 3.99 ± 16.83 | 4.55 ± 20.21 |
| Cycle 23 Day 15 | 0.23 ± 17.19 | 6.32 ± 23.53 |
| Cycle 24 Day 15 | 5.26 ± 17.27 | 8.33 ± 21.42 |
| Cycle 25 Day 15 | 6.18 ± 19.00 | 6.67 ± 23.97 |
| Cycle 26 Day 15 | 5.21 ± 20.38 | 4.39 ± 16.75 |
| Cycle 27 Day 15 | 11.67 ± 17.18 | 16.03 ± 27.74 |
| Cycle 28 Day 15 | 9.44 ± 15.39 | 9.17 ± 27.62 |
| Cycle 29 Day 15 | 8.33 ± 13.48 | 14.17 ± 32.64 |
| Cycle 30 Day 15 | 9.72 ± 9.95 | 5.95 ± 12.47 |
| EOT | -5.62 ± 21.42 | -3.25 ± 21.64 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of physical functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -1.67 ± 17.24 | -2.50 ± 15.85 |
| Cycle 3 Day 15 | -1.98 ± 15.74 | -0.67 ± 17.01 |
| Cycle 4 Day 15 | -0.98 ± 14.62 | -1.20 ± 18.63 |
| Cycle 5 Day 15 | -1.41 ± 15.23 | -0.33 ± 18.25 |
| Cycle 6 Day 15 | -1.05 ± 14.79 | 0.84 ± 17.45 |
| Cycle 7 Day 15 | -1.94 ± 15.08 | -0.42 ± 17.82 |
| Cycle 8 Day 15 | -0.60 ± 15.54 | 0.59 ± 18.81 |
| Cycle 9 Day 15 | -2.77 ± 16.01 | 0.34 ± 18.40 |
| Cycle 10 Day 15 | -1.21 ± 15.30 | 0.81 ± 19.02 |
| Cycle 11 Day 15 | -2.37 ± 14.73 | 0.11 ± 18.43 |
| Cycle 12 Day 15 | -0.87 ± 12.95 | 0.41 ± 19.32 |
| Cycle 13 Day 15 | -1.29 ± 13.50 | -1.48 ± 19.60 |
| Cycle 14 Day 15 | -1.89 ± 12.01 | -0.32 ± 18.68 |
| Cycle 15 Day 15 | -3.33 ± 14.48 | 0.00 ± 23.19 |
| Cycle 16 Day 15 | -1.65 ± 16.36 | -0.07 ± 18.89 |
| Cycle 17 Day 15 | -2.87 ± 14.11 | -2.54 ± 21.31 |
| Cycle 18 Day 15 | -4.71 ± 17.32 | -2.29 ± 20.52 |
| Cycle 19 Day 15 | -3.98 ± 15.99 | -2.26 ± 18.96 |
| Cycle 20 Day 15 | -2.89 ± 15.11 | -2.32 ± 19.02 |
| Cycle 21 Day 15 | -4.97 ± 15.02 | 2.98 ± 20.19 |
| Cycle 22 Day 15 | -3.62 ± 16.01 | 3.64 ± 18.11 |
| Cycle 23 Day 15 | -6.67 ± 15.94 | -2.30 ± 24.38 |
| Cycle 24 Day 15 | -4.21 ± 17.29 | 1.67 ± 24.42 |
| Cycle 25 Day 15 | -4.73 ± 17.14 | -1.67 ± 22.98 |
| Cycle 26 Day 15 | -2.50 ± 19.24 | -2.11 ± 16.93 |
| Cycle 27 Day 15 | 2.67 ± 15.81 | 4.62 ± 26.02 |
| Cycle 28 Day 15 | -0.44 ± 13.68 | 4.67 ± 23.94 |
| Cycle 29 Day 15 | -0.48 ± 13.45 | 5.33 ± 23.26 |
| Cycle 30 Day 15 | 5.00 ± 15.86 | -0.95 ± 15.12 |
| EOT | -8.76 ± 21.78 | -7.60 ± 20.03 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of role functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -4.79 ± 22.56 | -1.75 ± 24.86 |
| Cycle 3 Day 15 | -2.42 ± 22.86 | -1.12 ± 27.08 |
| Cycle 4 Day 15 | -0.75 ± 22.43 | 1.65 ± 26.71 |
| Cycle 5 Day 15 | -2.71 ± 20.70 | -0.41 ± 28.89 |
| Cycle 6 Day 15 | -1.83 ± 21.72 | 0.44 ± 27.58 |
| Cycle 7 Day 15 | -2.66 ± 22.79 | 2.80 ± 29.80 |
| Cycle 8 Day 15 | -1.63 ± 20.50 | -2.22 ± 32.37 |
| Cycle 9 Day 15 | -4.23 ± 21.40 | -2.54 ± 31.25 |
| Cycle 10 Day 15 | -3.72 ± 19.66 | 2.17 ± 28.79 |
| Cycle 11 Day 15 | -2.48 ± 18.84 | -1.98 ± 31.74 |
| Cycle 12 Day 15 | -2.34 ± 18.94 | -0.29 ± 30.62 |
| Cycle 13 Day 15 | -3.72 ± 18.51 | -1.52 ± 28.78 |
| Cycle 14 Day 15 | -6.73 ± 18.28 | -2.70 ± 30.15 |
| Cycle 15 Day 15 | -7.64 ± 20.36 | -3.00 ± 31.46 |
| Cycle 16 Day 15 | -3.33 ± 19.38 | -3.23 ± 30.52 |
| Cycle 17 Day 15 | -8.23 ± 17.47 | -4.76 ± 32.27 |
| Cycle 18 Day 15 | -9.07 ± 23.65 | -3.10 ± 27.55 |
| Cycle 19 Day 15 | -5.38 ± 20.64 | -5.37 ± 26.16 |
| Cycle 20 Day 15 | -5.97 ± 18.23 | -1.09 ± 27.98 |
| Cycle 21 Day 15 | -6.21 ± 18.25 | -0.88 ± 28.46 |
| Cycle 22 Day 15 | -5.80 ± 16.93 | -0.51 ± 30.76 |
| Cycle 23 Day 15 | -6.02 ± 14.99 | -5.17 ± 33.36 |
| Cycle 24 Day 15 | -4.82 ± 17.29 | 1.39 ± 39.90 |
| Cycle 25 Day 15 | -4.30 ± 16.08 | -4.17 ± 38.95 |
| Cycle 26 Day 15 | -6.25 ± 21.88 | -7.89 ± 31.12 |
| Cycle 27 Day 15 | -0.83 ± 17.50 | 1.28 ± 31.52 |
| Cycle 28 Day 15 | -4.44 ± 9.89 | -11.67 ± 35.18 |
| Cycle 29 Day 15 | -2.38 ± 12.84 | -10.00 ± 34.43 |
| Cycle 30 Day 15 | 4.17 ± 22.61 | -4.76 ± 29.99 |
| EOT | -11.24 ± 26.08 | -8.00 ± 26.54 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of emotional functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -1.29 ± 17.92 | 2.50 ± 17.94 |
| Cycle 3 Day 15 | 0.71 ± 14.50 | 1.31 ± 19.12 |
| Cycle 4 Day 15 | -0.27 ± 17.52 | 3.39 ± 20.33 |
| Cycle 5 Day 15 | 0.35 ± 17.39 | 1.78 ± 18.53 |
| Cycle 6 Day 15 | 1.83 ± 17.22 | 1.78 ± 19.08 |
| Cycle 7 Day 15 | 1.10 ± 19.17 | 2.51 ± 19.73 |
| Cycle 8 Day 15 | 2.01 ± 17.23 | 2.41 ± 19.71 |
| Cycle 9 Day 15 | -0.64 ± 18.08 | 3.53 ± 22.84 |
| Cycle 10 Day 15 | 0.28 ± 16.73 | 2.10 ± 19.60 |
| Cycle 11 Day 15 | 1.31 ± 17.61 | 1.41 ± 22.55 |
| Cycle 12 Day 15 | 1.25 ± 17.28 | 1.33 ± 21.49 |
| Cycle 13 Day 15 | 0.81 ± 17.13 | 0.51 ± 20.54 |
| Cycle 14 Day 15 | 1.26 ± 17.55 | 0.16 ± 19.68 |
| Cycle 15 Day 15 | 0.61 ± 18.86 | -0.50 ± 20.34 |
| Cycle 16 Day 15 | -0.39 ± 17.05 | -0.90 ± 18.69 |
| Cycle 17 Day 15 | 0.21 ± 16.23 | -3.27 ± 21.06 |
| Cycle 18 Day 15 | -2.57 ± 16.31 | -1.19 ± 22.31 |
| Cycle 19 Day 15 | -2.15 ± 15.16 | -1.27 ± 22.31 |
| Cycle 20 Day 15 | 0.63 ± 14.79 | -1.81 ± 24.27 |
| Cycle 21 Day 15 | -0.82 ± 15.57 | 1.54 ± 22.99 |
| Cycle 22 Day 15 | 1.09 ± 15.48 | 3.54 ± 24.30 |
| Cycle 23 Day 15 | -2.31 ± 15.64 | 0.57 ± 28.17 |
| Cycle 24 Day 15 | -1.10 ± 17.78 | 4.17 ± 27.58 |
| Cycle 25 Day 15 | 4.84 ± 15.03 | -7.08 ± 29.90 |
| Cycle 26 Day 15 | 3.13 ± 20.97 | -1.75 ± 31.98 |
| Cycle 27 Day 15 | 5.83 ± 17.54 | 8.97 ± 16.83 |
| Cycle 28 Day 15 | 12.78 ± 24.77 | 4.17 ± 14.30 |
| Cycle 29 Day 15 | 5.95 ± 15.82 | 10.00 ± 9.46 |
| Cycle 30 Day 15 | 9.03 ± 24.74 | 9.52 ± 15.54 |
| EOT | -6.37 ± 17.23 | -3.25 ± 19.85 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of cognitive functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -1.42 ± 16.01 | 0.25 ± 19.52 |
| Cycle 3 Day 15 | -1.21 ± 18.37 | -1.78 ± 19.45 |
| Cycle 4 Day 15 | -1.07 ± 18.71 | 1.07 ± 17.77 |
| Cycle 5 Day 15 | -2.51 ± 16.68 | 0.20 ± 18.92 |
| Cycle 6 Day 15 | -2.28 ± 16.80 | 0.33 ± 18.37 |
| Cycle 7 Day 15 | -1.16 ± 17.26 | 0.00 ± 18.76 |
| Cycle 8 Day 15 | -1.88 ± 15.17 | -1.73 ± 20.39 |
| Cycle 9 Day 15 | -4.36 ± 17.31 | 1.69 ± 18.79 |
| Cycle 10 Day 15 | -4.68 ± 15.84 | -1.36 ± 20.09 |
| Cycle 11 Day 15 | -5.10 ± 16.78 | -1.41 ± 19.92 |
| Cycle 12 Day 15 | -4.21 ± 17.15 | 0.29 ± 20.53 |
| Cycle 13 Day 15 | -5.18 ± 16.83 | 0.34 ± 20.06 |
| Cycle 14 Day 15 | -5.72 ± 18.16 | -1.27 ± 20.76 |
| Cycle 15 Day 15 | -6.08 ± 19.21 | -3.50 ± 19.29 |
| Cycle 16 Day 15 | -4.51 ± 17.70 | -3.58 ± 19.48 |
| Cycle 17 Day 15 | -5.27 ± 16.78 | -4.76 ± 22.34 |
| Cycle 18 Day 15 | -10.29 ± 20.57 | -2.38 ± 18.88 |
| Cycle 19 Day 15 | -8.06 ± 18.29 | -5.65 ± 17.94 |
| Cycle 20 Day 15 | -8.81 ± 17.48 | -3.99 ± 18.32 |
| Cycle 21 Day 15 | -9.80 ± 17.05 | -1.75 ± 14.39 |
| Cycle 22 Day 15 | -6.88 ± 17.42 | -3.54 ± 15.45 |
| Cycle 23 Day 15 | -5.56 ± 16.90 | -5.17 ± 19.47 |
| Cycle 24 Day 15 | -12.28 ± 19.25 | -1.39 ± 18.33 |
| Cycle 25 Day 15 | -13.98 ± 19.77 | -7.50 ± 23.24 |
| Cycle 26 Day 15 | -14.58 ± 23.73 | -6.14 ± 14.92 |
| Cycle 27 Day 15 | -5.83 ± 17.33 | -3.85 ± 21.68 |
| Cycle 28 Day 15 | -11.11 ± 13.61 | -5.00 ± 11.25 |
| Cycle 29 Day 15 | -11.90 ± 13.76 | -5.00 ± 13.72 |
| Cycle 30 Day 15 | -8.33 ± 16.67 | -2.38 ± 17.82 |
| EOT | -7.87 ± 21.92 | -1.83 ± 24.03 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of social functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -0.80 ± 21.69 | 0.08 ± 21.23 |
| Cycle 3 Day 15 | -0.51 ± 21.73 | 2.43 ± 24.17 |
| Cycle 4 Day 15 | -0.11 ± 20.08 | 2.23 ± 24.91 |
| Cycle 5 Day 15 | 0.40 ± 22.69 | 1.73 ± 24.04 |
| Cycle 6 Day 15 | -1.03 ± 24.70 | 2.22 ± 24.25 |
| Cycle 7 Day 15 | 1.27 ± 22.57 | 3.85 ± 27.10 |
| Cycle 8 Day 15 | 0.38 ± 23.16 | 0.74 ± 23.82 |
| Cycle 9 Day 15 | 0.90 ± 24.67 | 0.28 ± 24.07 |
| Cycle 10 Day 15 | -1.24 ± 24.92 | -0.41 ± 23.32 |
| Cycle 11 Day 15 | 0.14 ± 21.99 | 1.69 ± 25.26 |
| Cycle 12 Day 15 | 2.02 ± 22.63 | -2.06 ± 24.61 |
| Cycle 13 Day 15 | -1.13 ± 21.55 | 1.01 ± 24.49 |
| Cycle 14 Day 15 | -4.04 ± 22.35 | -1.43 ± 26.36 |
| Cycle 15 Day 15 | -1.39 ± 22.38 | -0.33 ± 27.11 |
| Cycle 16 Day 15 | 1.96 ± 19.66 | 0.36 ± 22.52 |
| Cycle 17 Day 15 | -2.95 ± 20.97 | -0.99 ± 27.67 |
| Cycle 18 Day 15 | -2.21 ± 25.90 | -0.71 ± 24.48 |
| Cycle 19 Day 15 | 0.27 ± 20.58 | 3.11 ± 22.63 |
| Cycle 20 Day 15 | 0.94 ± 22.51 | 0.72 ± 24.08 |
| Cycle 21 Day 15 | -1.31 ± 22.81 | 3.51 ± 27.44 |
| Cycle 22 Day 15 | 0.00 ± 20.49 | 4.04 ± 27.65 |
| Cycle 23 Day 15 | -0.46 ± 20.50 | 2.30 ± 29.79 |
| Cycle 24 Day 15 | 0.00 ± 20.13 | 3.47 ± 27.35 |
| Cycle 25 Day 15 | 0.00 ± 20.64 | 3.33 ± 27.36 |
| Cycle 26 Day 15 | 5.56 ± 20.66 | 4.39 ± 25.36 |
| Cycle 27 Day 15 | 11.67 ± 18.81 | 7.69 ± 27.74 |
| Cycle 28 Day 15 | 11.11 ± 17.44 | 0.00 ± 17.57 |
| Cycle 29 Day 15 | 7.14 ± 19.30 | -6.67 ± 17.92 |
| Cycle 30 Day 15 | 9.72 ± 26.07 | 7.14 ± 30.21 |
| EOT | -8.43 ± 25.14 | -5.17 ± 30.31 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 3.66 ± 20.39 | 3.94 ± 19.99 |
| Cycle 3 Day 15 | 3.91 ± 21.49 | 2.25 ± 20.30 |
| Cycle 4 Day 15 | 0.71 ± 19.70 | 0.97 ± 20.35 |
| Cycle 5 Day 15 | 1.41 ± 19.04 | 0.61 ± 20.75 |
| Cycle 6 Day 15 | -0.91 ± 19.98 | 0.52 ± 20.69 |
| Cycle 7 Day 15 | 0.77 ± 18.29 | -0.31 ± 21.79 |
| Cycle 8 Day 15 | 0.00 ± 18.35 | 1.81 ± 23.71 |
| Cycle 9 Day 15 | 2.99 ± 21.51 | 0.85 ± 22.65 |
| Cycle 10 Day 15 | 1.56 ± 22.05 | 1.54 ± 19.83 |
| Cycle 11 Day 15 | 2.85 ± 20.96 | 2.73 ± 19.10 |
| Cycle 12 Day 15 | 1.25 ± 17.22 | 0.39 ± 20.57 |
| Cycle 13 Day 15 | 0.65 ± 19.11 | 1.80 ± 18.83 |
| Cycle 14 Day 15 | 2.69 ± 17.82 | 1.90 ± 20.00 |
| Cycle 15 Day 15 | 2.89 ± 18.68 | 1.33 ± 21.73 |
| Cycle 16 Day 15 | 3.53 ± 20.30 | 2.75 ± 20.83 |
| Cycle 17 Day 15 | 2.95 ± 17.22 | 2.38 ± 23.40 |
| Cycle 18 Day 15 | 5.39 ± 24.24 | 1.27 ± 20.94 |
| Cycle 19 Day 15 | 6.09 ± 19.37 | 4.14 ± 19.67 |
| Cycle 20 Day 15 | 5.24 ± 19.32 | 0.48 ± 18.88 |
| Cycle 21 Day 15 | 3.49 ± 21.14 | -2.63 ± 20.08 |
| Cycle 22 Day 15 | 3.86 ± 19.35 | -4.71 ± 22.40 |
| Cycle 23 Day 15 | 4.32 ± 21.79 | -3.07 ± 22.40 |
| Cycle 24 Day 15 | 0.88 ± 20.40 | -3.70 ± 24.45 |
| Cycle 25 Day 15 | 2.51 ± 21.79 | -1.11 ± 27.19 |
| Cycle 26 Day 15 | -0.46 ± 22.58 | -1.75 ± 24.08 |
| Cycle 27 Day 15 | -1.67 ± 17.01 | -8.55 ± 22.75 |
| Cycle 28 Day 15 | 0.74 ± 20.77 | -6.67 ± 16.73 |
| Cycle 29 Day 15 | 5.56 ± 18.87 | -6.67 ± 17.53 |
| Cycle 30 Day 15 | -2.78 ± 17.81 | -15.87 ± 23.00 |
| EOT | 9.99 ± 27.22 | 3.56 ± 21.59 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 0.44 ± 13.18 | 0.92 ± 12.75 |
| Cycle 3 Day 15 | -2.22 ± 10.34 | -0.94 ± 13.69 |
| Cycle 4 Day 15 | -1.92 ± 11.19 | 0.19 ± 14.53 |
| Cycle 5 Day 15 | -1.20 ± 11.97 | -0.30 ± 13.75 |
| Cycle 6 Day 15 | -2.74 ± 11.58 | 0.22 ± 11.09 |
| Cycle 7 Day 15 | -1.62 ± 11.21 | -0.12 ± 11.95 |
| Cycle 8 Day 15 | -1.50 ± 11.51 | -0.74 ± 13.33 |
| Cycle 9 Day 15 | -0.38 ± 13.84 | -0.56 ± 11.10 |
| Cycle 10 Day 15 | -0.41 ± 11.48 | 0.27 ± 13.83 |
| Cycle 11 Day 15 | -1.52 ± 14.91 | -0.56 ± 12.31 |
| Cycle 12 Day 15 | -1.09 ± 13.79 | 0.15 ± 13.27 |
| Cycle 13 Day 15 | -1.62 ± 15.22 | -0.34 ± 17.17 |
| Cycle 14 Day 15 | -0.84 ± 15.68 | 1.43 ± 14.82 |
| Cycle 15 Day 15 | -1.04 ± 12.75 | -0.67 ± 12.29 |
| Cycle 16 Day 15 | -1.18 ± 12.28 | -0.90 ± 14.19 |
| Cycle 17 Day 15 | 1.05 ± 11.11 | 0.99 ± 18.54 |
| Cycle 18 Day 15 | -0.49 ± 9.54 | 0.95 ± 13.27 |
| Cycle 19 Day 15 | 1.08 ± 15.35 | 3.11 ± 18.17 |
| Cycle 20 Day 15 | -1.57 ± 8.81 | 2.17 ± 15.56 |
| Cycle 21 Day 15 | 0.00 ± 10.00 | 2.63 ± 17.12 |
| Cycle 22 Day 15 | 1.45 ± 8.48 | 3.03 ± 16.38 |
| Cycle 23 Day 15 | 2.78 ± 10.91 | 1.72 ± 9.28 |
| Cycle 24 Day 15 | -0.44 ± 9.08 | 2.78 ± 6.34 |
| Cycle 25 Day 15 | -0.54 ± 11.77 | 0.83 ± 6.57 |
| Cycle 26 Day 15 | 0.00 ± 12.04 | 4.39 ± 13.43 |
| Cycle 27 Day 15 | -0.83 ± 12.65 | 1.28 ± 8.23 |
| Cycle 28 Day 15 | -2.22 ± 10.67 | 1.67 ± 5.27 |
| Cycle 29 Day 15 | 0.00 ± 16.01 | 1.67 ± 5.27 |
| Cycle 30 Day 15 | -2.78 ± 11.96 | 2.38 ± 6.30 |
| EOT | 1.69 ± 20.26 | -1.33 ± 16.70 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -3.63 ± 26.70 | -5.50 ± 24.51 |
| Cycle 3 Day 15 | -6.36 ± 22.50 | -8.80 ± 25.68 |
| Cycle 4 Day 15 | -7.48 ± 19.70 | -6.59 ± 25.08 |
| Cycle 5 Day 15 | -6.02 ± 21.88 | -8.64 ± 26.01 |
| Cycle 6 Day 15 | -6.96 ± 21.51 | -8.67 ± 26.31 |
| Cycle 7 Day 15 | -6.83 ± 22.42 | -9.21 ± 28.44 |
| Cycle 8 Day 15 | -7.02 ± 19.59 | -4.32 ± 25.35 |
| Cycle 9 Day 15 | -8.46 ± 23.04 | -4.66 ± 25.49 |
| Cycle 10 Day 15 | -4.55 ± 22.05 | -6.64 ± 26.11 |
| Cycle 11 Day 15 | -4.82 ± 21.88 | -5.51 ± 25.04 |
| Cycle 12 Day 15 | -4.67 ± 21.81 | -5.31 ± 24.63 |
| Cycle 13 Day 15 | -3.07 ± 21.23 | -4.21 ± 25.90 |
| Cycle 14 Day 15 | -4.21 ± 22.25 | -2.86 ± 25.99 |
| Cycle 15 Day 15 | -2.08 ± 21.39 | -3.83 ± 25.50 |
| Cycle 16 Day 15 | -3.53 ± 22.87 | -3.76 ± 23.71 |
| Cycle 17 Day 15 | -0.84 ± 21.00 | -0.99 ± 26.68 |
| Cycle 18 Day 15 | -0.98 ± 17.96 | -2.62 ± 25.00 |
| Cycle 19 Day 15 | -1.08 ± 20.22 | -2.26 ± 26.16 |
| Cycle 20 Day 15 | -1.89 ± 18.68 | -6.52 ± 31.91 |
| Cycle 21 Day 15 | 0.65 ± 18.84 | -10.09 ± 30.64 |
| Cycle 22 Day 15 | -3.62 ± 18.23 | -4.55 ± 33.92 |
| Cycle 23 Day 15 | 3.24 ± 17.28 | -4.60 ± 35.88 |
| Cycle 24 Day 15 | 1.32 ± 20.64 | -6.94 ± 34.37 |
| Cycle 25 Day 15 | 0.54 ± 17.99 | -5.83 ± 30.72 |
| Cycle 26 Day 15 | 2.78 ± 18.82 | -11.40 ± 34.27 |
| Cycle 27 Day 15 | -0.83 ± 19.85 | -2.56 ± 31.80 |
| Cycle 28 Day 15 | 4.44 ± 20.38 | -11.67 ± 28.38 |
| Cycle 29 Day 15 | 9.52 ± 12.60 | -11.67 ± 28.38 |
| Cycle 30 Day 15 | -8.33 ± 25.13 | -14.29 ± 20.25 |
| EOT | 3.56 ± 31.53 | 4.50 ± 23.31 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 5.14 ± 22.41 | 3.67 ± 21.60 |
| Cycle 3 Day 15 | 6.87 ± 25.10 | 1.12 ± 22.10 |
| Cycle 4 Day 15 | 4.91 ± 22.97 | 1.74 ± 20.16 |
| Cycle 5 Day 15 | 3.01 ± 24.84 | 3.25 ± 21.91 |
| Cycle 6 Day 15 | 4.57 ± 23.69 | 2.67 ± 19.89 |
| Cycle 7 Day 15 | 4.86 ± 23.97 | 1.17 ± 20.33 |
| Cycle 8 Day 15 | 6.77 ± 25.54 | 5.43 ± 22.75 |
| Cycle 9 Day 15 | 8.21 ± 25.27 | 2.54 ± 21.86 |
| Cycle 10 Day 15 | 4.68 ± 21.22 | 3.25 ± 22.75 |
| Cycle 11 Day 15 | 6.34 ± 24.84 | 3.11 ± 19.48 |
| Cycle 12 Day 15 | 5.61 ± 26.50 | 6.78 ± 23.21 |
| Cycle 13 Day 15 | 7.44 ± 24.67 | 5.72 ± 22.36 |
| Cycle 14 Day 15 | 5.72 ± 23.35 | 6.98 ± 22.02 |
| Cycle 15 Day 15 | 8.33 ± 23.69 | 6.67 ± 23.69 |
| Cycle 16 Day 15 | 5.49 ± 23.48 | 5.38 ± 21.59 |
| Cycle 17 Day 15 | 8.44 ± 20.30 | 7.14 ± 20.09 |
| Cycle 18 Day 15 | 9.80 ± 25.14 | 3.81 ± 20.88 |
| Cycle 19 Day 15 | 8.06 ± 23.13 | 11.86 ± 25.34 |
| Cycle 20 Day 15 | 6.92 ± 21.04 | 6.52 ± 18.08 |
| Cycle 21 Day 15 | 11.11 ± 21.77 | 9.65 ± 20.37 |
| Cycle 22 Day 15 | 7.97 ± 18.84 | 5.05 ± 20.62 |
| Cycle 23 Day 15 | 11.11 ± 25.20 | 4.60 ± 14.70 |
| Cycle 24 Day 15 | 10.53 ± 28.06 | 2.78 ± 19.45 |
| Cycle 25 Day 15 | 7.53 ± 16.58 | 6.67 ± 17.44 |
| Cycle 26 Day 15 | 9.72 ± 18.33 | 5.26 ± 20.07 |
| Cycle 27 Day 15 | 10.00 ± 19.04 | 5.13 ± 18.49 |
| Cycle 28 Day 15 | 11.11 ± 24.12 | 3.33 ± 18.92 |
| Cycle 29 Day 15 | 7.14 ± 19.30 | 10.00 ± 16.10 |
| Cycle 30 Day 15 | 2.78 ± 26.43 | -4.76 ± 12.60 |
| EOT | 10.11 ± 26.78 | 6.00 ± 21.39 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 0.71 ± 27.78 | -3.67 ± 27.31 |
| Cycle 3 Day 15 | -4.24 ± 26.84 | -4.68 ± 29.16 |
| Cycle 4 Day 15 | -5.56 ± 25.63 | -7.95 ± 30.08 |
| Cycle 5 Day 15 | -4.82 ± 29.19 | -2.85 ± 29.86 |
| Cycle 6 Day 15 | -3.65 ± 27.72 | -3.78 ± 28.78 |
| Cycle 7 Day 15 | -1.85 ± 26.38 | -3.26 ± 29.95 |
| Cycle 8 Day 15 | -2.51 ± 27.71 | -5.19 ± 26.66 |
| Cycle 9 Day 15 | -2.31 ± 27.28 | -7.06 ± 30.77 |
| Cycle 10 Day 15 | -0.55 ± 24.34 | -4.07 ± 30.35 |
| Cycle 11 Day 15 | -1.10 ± 27.53 | -1.13 ± 29.54 |
| Cycle 12 Day 15 | -2.18 ± 26.41 | -7.37 ± 29.46 |
| Cycle 13 Day 15 | -3.88 ± 27.34 | -5.39 ± 26.81 |
| Cycle 14 Day 15 | 0.00 ± 29.74 | -1.90 ± 27.28 |
| Cycle 15 Day 15 | 2.43 ± 27.46 | -4.33 ± 24.00 |
| Cycle 16 Day 15 | -1.57 ± 26.18 | -4.66 ± 25.82 |
| Cycle 17 Day 15 | -2.53 ± 24.33 | -3.97 ± 28.06 |
| Cycle 18 Day 15 | 0.98 ± 26.37 | -5.24 ± 28.17 |
| Cycle 19 Day 15 | 3.23 ± 26.80 | -2.82 ± 27.88 |
| Cycle 20 Day 15 | -3.14 ± 26.36 | -1.45 ± 22.17 |
| Cycle 21 Day 15 | -0.65 ± 24.49 | -4.39 ± 22.15 |
| Cycle 22 Day 15 | 0.00 ± 25.34 | -3.03 ± 25.50 |
| Cycle 23 Day 15 | -0.93 ± 27.01 | -2.30 ± 32.04 |
| Cycle 24 Day 15 | -5.26 ± 27.43 | -2.78 ± 27.66 |
| Cycle 25 Day 15 | -4.30 ± 28.21 | 0.00 ± 26.49 |
| Cycle 26 Day 15 | -1.39 ± 33.30 | -3.51 ± 15.29 |
| Cycle 27 Day 15 | -6.67 ± 23.20 | 5.13 ± 18.49 |
| Cycle 28 Day 15 | 0.00 ± 21.82 | 3.33 ± 18.92 |
| Cycle 29 Day 15 | -4.76 ± 25.68 | 3.33 ± 24.60 |
| Cycle 30 Day 15 | -11.11 ± 16.41 | 9.52 ± 16.27 |
| EOT | -1.50 ± 31.35 | -5.33 ± 31.33 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -0.35 ± 22.60 | 1.50 ± 20.68 |
| Cycle 3 Day 15 | -4.44 ± 18.60 | -2.43 ± 23.51 |
| Cycle 4 Day 15 | -4.06 ± 21.86 | -0.39 ± 22.51 |
| Cycle 5 Day 15 | -3.41 ± 20.64 | -0.81 ± 23.92 |
| Cycle 6 Day 15 | -6.39 ± 22.60 | -3.33 ± 22.77 |
| Cycle 7 Day 15 | -5.79 ± 20.23 | -2.33 ± 21.54 |
| Cycle 8 Day 15 | -4.76 ± 19.74 | -1.73 ± 23.15 |
| Cycle 9 Day 15 | -2.82 ± 27.54 | -0.56 ± 20.43 |
| Cycle 10 Day 15 | -3.86 ± 19.34 | -0.27 ± 20.69 |
| Cycle 11 Day 15 | -1.10 ± 23.54 | -1.98 ± 23.59 |
| Cycle 12 Day 15 | -1.87 ± 26.24 | -2.06 ± 21.95 |
| Cycle 13 Day 15 | -1.62 ± 20.55 | -3.03 ± 22.88 |
| Cycle 14 Day 15 | -2.69 ± 26.37 | -0.32 ± 22.41 |
| Cycle 15 Day 15 | -1.74 ± 21.83 | -0.33 ± 27.01 |
| Cycle 16 Day 15 | -6.67 ± 24.01 | -1.79 ± 23.76 |
| Cycle 17 Day 15 | -4.64 ± 19.05 | -0.40 ± 22.25 |
| Cycle 18 Day 15 | -2.94 ± 23.56 | 0.00 ± 19.66 |
| Cycle 19 Day 15 | -3.23 ± 23.15 | 2.82 ± 20.80 |
| Cycle 20 Day 15 | -3.77 ± 23.26 | 2.90 ± 23.12 |
| Cycle 21 Day 15 | -3.92 ± 21.75 | -1.75 ± 17.24 |
| Cycle 22 Day 15 | -2.17 ± 24.75 | -2.02 ± 14.29 |
| Cycle 23 Day 15 | -4.63 ± 24.11 | 0.00 ± 25.20 |
| Cycle 24 Day 15 | -2.63 ± 28.35 | -1.39 ± 23.01 |
| Cycle 25 Day 15 | -2.15 ± 27.13 | 1.67 ± 22.88 |
| Cycle 26 Day 15 | -2.78 ± 30.95 | 0.00 ± 11.11 |
| Cycle 27 Day 15 | -3.33 ± 32.26 | -7.69 ± 14.62 |
| Cycle 28 Day 15 | -11.11 ± 20.57 | -10.00 ± 16.10 |
| Cycle 29 Day 15 | -11.90 ± 21.11 | -10.00 ± 16.10 |
| Cycle 30 Day 15 | -13.89 ± 22.29 | -9.52 ± 16.27 |
| EOT | 7.49 ± 35.09 | 3.67 ± 29.17 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 4.79 ± 25.70 | 3.83 ± 27.59 |
| Cycle 3 Day 15 | 5.86 ± 26.79 | 9.74 ± 28.87 |
| Cycle 4 Day 15 | 6.20 ± 24.48 | 8.14 ± 28.58 |
| Cycle 5 Day 15 | 7.43 ± 28.04 | 5.69 ± 28.98 |
| Cycle 6 Day 15 | 7.08 ± 23.56 | 6.00 ± 28.92 |
| Cycle 7 Day 15 | 7.18 ± 26.20 | 4.43 ± 30.19 |
| Cycle 8 Day 15 | 7.02 ± 26.61 | 2.47 ± 27.21 |
| Cycle 9 Day 15 | 5.13 ± 24.36 | 4.80 ± 23.58 |
| Cycle 10 Day 15 | 3.58 ± 22.69 | 7.32 ± 25.08 |
| Cycle 11 Day 15 | 4.13 ± 23.40 | 5.08 ± 27.78 |
| Cycle 12 Day 15 | 2.80 ± 21.04 | 6.49 ± 29.16 |
| Cycle 13 Day 15 | 6.47 ± 23.37 | 7.07 ± 27.47 |
| Cycle 14 Day 15 | 5.05 ± 23.02 | 7.62 ± 25.84 |
| Cycle 15 Day 15 | 4.86 ± 25.58 | 3.33 ± 25.73 |
| Cycle 16 Day 15 | 2.75 ± 21.95 | 5.73 ± 29.33 |
| Cycle 17 Day 15 | 4.22 ± 22.88 | 11.51 ± 29.50 |
| Cycle 18 Day 15 | 6.86 ± 26.11 | 6.19 ± 27.97 |
| Cycle 19 Day 15 | 4.30 ± 25.24 | 5.65 ± 27.09 |
| Cycle 20 Day 15 | 2.52 ± 23.43 | 5.80 ± 25.63 |
| Cycle 21 Day 15 | 7.84 ± 20.64 | 4.39 ± 29.17 |
| Cycle 22 Day 15 | 7.97 ± 21.30 | 5.05 ± 33.46 |
| Cycle 23 Day 15 | 5.56 ± 16.90 | 0.00 ± 25.20 |
| Cycle 24 Day 15 | 8.77 ± 22.84 | 2.78 ± 30.95 |
| Cycle 25 Day 15 | 7.53 ± 22.29 | 5.00 ± 34.67 |
| Cycle 26 Day 15 | 4.17 ± 20.41 | -1.75 ± 28.27 |
| Cycle 27 Day 15 | -1.67 ± 20.16 | 7.69 ± 33.76 |
| Cycle 28 Day 15 | -4.44 ± 17.21 | 0.00 ± 27.22 |
| Cycle 29 Day 15 | 4.76 ± 25.68 | 0.00 ± 22.22 |
| Cycle 30 Day 15 | -2.78 ± 17.16 | -4.76 ± 23.00 |
| EOT | 3.00 ± 30.00 | -0.33 ± 24.84 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -3.19 ± 21.84 | -3.33 ± 23.86 |
| Cycle 3 Day 15 | -4.65 ± 24.11 | -5.62 ± 23.36 |
| Cycle 4 Day 15 | -4.70 ± 19.84 | -2.13 ± 24.75 |
| Cycle 5 Day 15 | -4.22 ± 20.49 | -3.46 ± 23.53 |
| Cycle 6 Day 15 | -0.91 ± 21.06 | -3.11 ± 23.91 |
| Cycle 7 Day 15 | -2.78 ± 20.67 | -3.96 ± 25.79 |
| Cycle 8 Day 15 | -5.26 ± 20.86 | -3.70 ± 25.32 |
| Cycle 9 Day 15 | -4.36 ± 24.69 | -3.67 ± 26.07 |
| Cycle 10 Day 15 | -2.48 ± 26.23 | -0.81 ± 25.77 |
| Cycle 11 Day 15 | -3.86 ± 22.85 | -4.52 ± 23.84 |
| Cycle 12 Day 15 | -4.05 ± 24.96 | -4.13 ± 24.04 |
| Cycle 13 Day 15 | -0.65 ± 24.24 | -2.69 ± 24.60 |
| Cycle 14 Day 15 | -0.67 ± 22.33 | -3.17 ± 26.36 |
| Cycle 15 Day 15 | -2.78 ± 24.02 | -1.33 ± 21.15 |
| Cycle 16 Day 15 | -3.14 ± 25.52 | -1.43 ± 23.01 |
| Cycle 17 Day 15 | -4.64 ± 20.49 | 0.00 ± 25.87 |
| Cycle 18 Day 15 | -0.98 ± 25.08 | -5.71 ± 20.44 |
| Cycle 19 Day 15 | -5.38 ± 24.29 | -2.26 ± 25.42 |
| Cycle 20 Day 15 | -3.14 ± 27.94 | -2.17 ± 19.12 |
| Cycle 21 Day 15 | -5.88 ± 21.81 | -0.88 ± 21.21 |
| Cycle 22 Day 15 | -5.80 ± 24.65 | -3.03 ± 19.30 |
| Cycle 23 Day 15 | -4.63 ± 22.75 | -6.90 ± 18.64 |
| Cycle 24 Day 15 | -5.26 ± 27.43 | -1.39 ± 18.33 |
| Cycle 25 Day 15 | -1.08 ± 21.92 | -8.33 ± 14.81 |
| Cycle 26 Day 15 | -1.39 ± 25.02 | -7.02 ± 21.02 |
| Cycle 27 Day 15 | -6.67 ± 20.52 | -5.13 ± 12.52 |
| Cycle 28 Day 15 | -11.11 ± 24.12 | -10.00 ± 16.10 |
| Cycle 29 Day 15 | -14.29 ± 21.54 | -3.33 ± 18.92 |
| Cycle 30 Day 15 | -11.11 ± 29.59 | -4.76 ± 12.60 |
| EOT | -1.50 ± 22.42 | -4.33 ± 24.92 |
EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of financial difficulties. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -2.66 ± 21.50 | -5.00 ± 24.50 |
| Cycle 3 Day 15 | -2.63 ± 22.69 | -4.68 ± 28.51 |
| Cycle 4 Day 15 | -1.50 ± 22.51 | -3.68 ± 28.03 |
| Cycle 5 Day 15 | -3.41 ± 22.51 | -4.27 ± 30.03 |
| Cycle 6 Day 15 | -0.68 ± 21.25 | -3.78 ± 31.02 |
| Cycle 7 Day 15 | -1.62 ± 23.10 | -4.43 ± 31.71 |
| Cycle 8 Day 15 | -3.76 ± 21.58 | -3.46 ± 32.65 |
| Cycle 9 Day 15 | 0.77 ± 24.72 | -6.21 ± 30.18 |
| Cycle 10 Day 15 | -2.75 ± 24.57 | -4.61 ± 29.36 |
| Cycle 11 Day 15 | -1.93 ± 21.21 | -5.93 ± 29.12 |
| Cycle 12 Day 15 | -2.49 ± 24.95 | -3.54 ± 29.33 |
| Cycle 13 Day 15 | -2.91 ± 23.85 | -3.03 ± 30.15 |
| Cycle 14 Day 15 | -1.01 ± 24.49 | -3.17 ± 27.16 |
| Cycle 15 Day 15 | 1.04 ± 27.12 | -2.33 ± 28.92 |
| Cycle 16 Day 15 | -2.35 ± 25.09 | -0.72 ± 27.35 |
| Cycle 17 Day 15 | 0.84 ± 21.33 | -4.37 ± 28.71 |
| Cycle 18 Day 15 | -1.96 ± 25.03 | -3.81 ± 28.11 |
| Cycle 19 Day 15 | -2.69 ± 24.37 | -5.08 ± 30.83 |
| Cycle 20 Day 15 | -5.03 ± 22.07 | -3.62 ± 33.87 |
| Cycle 21 Day 15 | -6.54 ± 23.11 | -7.02 ± 30.17 |
| Cycle 22 Day 15 | -8.70 ± 21.59 | -7.07 ± 30.91 |
| Cycle 23 Day 15 | -5.56 ± 23.23 | -5.75 ± 29.64 |
| Cycle 24 Day 15 | -5.26 ± 27.43 | -9.72 ± 28.62 |
| Cycle 25 Day 15 | -8.60 ± 25.77 | -5.00 ± 39.40 |
| Cycle 26 Day 15 | -13.89 ± 21.80 | -3.51 ± 36.67 |
| Cycle 27 Day 15 | -16.67 ± 25.36 | -10.26 ± 43.85 |
| Cycle 28 Day 15 | -15.56 ± 24.77 | -3.33 ± 42.89 |
| Cycle 29 Day 15 | -14.29 ± 25.20 | -3.33 ± 39.91 |
| Cycle 30 Day 15 | -11.11 ± 21.71 | 4.76 ± 23.00 |
| EOT | 5.24 ± 23.52 | -1.33 ± 33.81 |
The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for disease symptoms and a positive change from baseline represents more symptoms, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | -4.59 ± 15.80 | -5.38 ± 15.58 |
| Cycle 3 Day 15 | -5.28 ± 15.74 | -5.91 ± 17.75 |
| Cycle 4 Day 15 | -5.08 ± 13.89 | -6.59 ± 16.90 |
| Cycle 5 Day 15 | -5.52 ± 16.55 | -8.63 ± 18.18 |
| Cycle 6 Day 15 | -6.66 ± 15.88 | -8.56 ± 19.26 |
| Cycle 7 Day 15 | -6.33 ± 15.79 | -8.51 ± 17.64 |
| Cycle 8 Day 15 | -4.72 ± 14.22 | -7.10 ± 19.56 |
| Cycle 9 Day 15 | -6.33 ± 16.43 | -7.52 ± 20.71 |
| Cycle 10 Day 15 | -4.87 ± 15.72 | -7.21 ± 18.25 |
| Cycle 11 Day 15 | -5.10 ± 14.48 | -7.57 ± 19.46 |
| Cycle 12 Day 15 | -4.83 ± 16.33 | -7.99 ± 18.92 |
| Cycle 13 Day 15 | -4.48 ± 16.54 | -5.44 ± 17.20 |
| Cycle 14 Day 15 | -5.16 ± 14.90 | -6.36 ± 17.25 |
| Cycle 15 Day 15 | -3.82 ± 16.49 | -5.67 ± 17.99 |
| Cycle 16 Day 15 | -5.82 ± 16.26 | -5.25 ± 17.65 |
| Cycle 17 Day 15 | -2.18 ± 14.22 | -4.02 ± 19.02 |
| Cycle 18 Day 15 | -0.66 ± 13.90 | -6.28 ± 17.95 |
| Cycle 19 Day 15 | -1.61 ± 12.50 | -6.13 ± 18.34 |
| Cycle 20 Day 15 | -3.25 ± 14.51 | -10.99 ± 18.93 |
| Cycle 21 Day 15 | -1.20 ± 13.58 | -8.92 ± 19.23 |
| Cycle 22 Day 15 | -2.54 ± 14.75 | -6.94 ± 22.04 |
| Cycle 23 Day 15 | -0.31 ± 11.26 | -7.14 ± 20.50 |
| Cycle 24 Day 15 | -1.61 ± 13.97 | -8.70 ± 20.30 |
| Cycle 25 Day 15 | -0.72 ± 16.34 | -9.72 ± 23.07 |
| Cycle 26 Day 15 | -2.31 ± 15.53 | -9.57 ± 19.41 |
| Cycle 27 Day 15 | -2.22 ± 16.16 | -10.68 ± 26.30 |
| Cycle 28 Day 15 | 0.00 ± 13.61 | -13.58 ± 24.07 |
| Cycle 29 Day 15 | 0.40 ± 6.34 | -15.00 ± 25.40 |
| Cycle 30 Day 15 | -4.17 ± 15.19 | -15.08 ± 17.19 |
| EOT | 2.40 ± 22.86 | 2.92 ± 19.77 |
The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for side effects of treatment and a positive change from baseline represents more side effects, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 1.94 ± 11.34 | 0.23 ± 12.22 |
| Cycle 3 Day 15 | 1.68 ± 11.26 | 0.45 ± 13.29 |
| Cycle 4 Day 15 | 2.23 ± 12.34 | 0.04 ± 14.86 |
| Cycle 5 Day 15 | 2.51 ± 12.18 | 1.75 ± 15.06 |
| Cycle 6 Day 15 | 1.18 ± 13.17 | -0.76 ± 13.28 |
| Cycle 7 Day 15 | 1.47 ± 13.01 | -0.42 ± 15.12 |
| Cycle 8 Day 15 | 0.97 ± 12.86 | 0.34 ± 14.70 |
| Cycle 9 Day 15 | 2.03 ± 13.58 | -0.05 ± 14.70 |
| Cycle 10 Day 15 | 3.64 ± 13.04 | 1.00 ± 14.46 |
| Cycle 11 Day 15 | 2.27 ± 13.49 | 1.03 ± 14.77 |
| Cycle 12 Day 15 | 2.08 ± 12.78 | 0.49 ± 15.06 |
| Cycle 13 Day 15 | 2.41 ± 13.79 | 0.31 ± 13.51 |
| Cycle 14 Day 15 | 4.18 ± 13.64 | 1.24 ± 15.14 |
| Cycle 15 Day 15 | 3.50 ± 12.13 | 0.71 ± 14.03 |
| Cycle 16 Day 15 | 3.72 ± 13.10 | 1.79 ± 14.73 |
| Cycle 17 Day 15 | 3.85 ± 10.71 | 2.06 ± 15.14 |
| Cycle 18 Day 15 | 3.99 ± 13.15 | 0.37 ± 13.34 |
| Cycle 19 Day 15 | 4.93 ± 13.54 | 0.94 ± 12.65 |
| Cycle 20 Day 15 | 3.87 ± 12.74 | 0.84 ± 16.03 |
| Cycle 21 Day 15 | 3.22 ± 12.70 | -0.99 ± 15.09 |
| Cycle 22 Day 15 | 2.10 ± 11.26 | -0.88 ± 18.18 |
| Cycle 23 Day 15 | 1.10 ± 11.83 | -1.32 ± 17.03 |
| Cycle 24 Day 15 | 0.56 ± 11.39 | -3.17 ± 16.57 |
| Cycle 25 Day 15 | 3.24 ± 13.69 | -1.30 ± 19.03 |
| Cycle 26 Day 15 | 1.88 ± 15.40 | -2.10 ± 15.04 |
| Cycle 27 Day 15 | 0.98 ± 14.42 | -3.33 ± 18.51 |
| Cycle 28 Day 15 | -0.27 ± 16.41 | -2.18 ± 14.63 |
| Cycle 29 Day 15 | 1.75 ± 13.47 | -3.78 ± 13.95 |
| Cycle 30 Day 15 | -2.69 ± 20.07 | -4.02 ± 12.18 |
| EOT | 2.95 ± 13.99 | 0.69 ± 13.93 |
The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for future perspectives and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 2.76 ± 19.18 | 5.47 ± 19.91 |
| Cycle 3 Day 15 | 3.96 ± 20.68 | 6.72 ± 22.14 |
| Cycle 4 Day 15 | 5.41 ± 22.33 | 9.73 ± 24.08 |
| Cycle 5 Day 15 | 4.31 ± 22.81 | 8.70 ± 22.38 |
| Cycle 6 Day 15 | 4.57 ± 21.71 | 8.81 ± 23.75 |
| Cycle 7 Day 15 | 5.28 ± 21.58 | 9.48 ± 24.03 |
| Cycle 8 Day 15 | 6.02 ± 19.41 | 8.27 ± 23.44 |
| Cycle 9 Day 15 | 4.48 ± 23.22 | 10.15 ± 24.01 |
| Cycle 10 Day 15 | 4.41 ± 18.67 | 8.17 ± 23.16 |
| Cycle 11 Day 15 | 4.87 ± 17.39 | 7.38 ± 25.33 |
| Cycle 12 Day 15 | 5.30 ± 17.29 | 6.25 ± 25.43 |
| Cycle 13 Day 15 | 5.07 ± 18.98 | 6.12 ± 25.03 |
| Cycle 14 Day 15 | 4.71 ± 21.48 | 5.24 ± 24.72 |
| Cycle 15 Day 15 | 3.59 ± 20.99 | 4.83 ± 26.76 |
| Cycle 16 Day 15 | 7.06 ± 21.54 | 7.37 ± 26.32 |
| Cycle 17 Day 15 | 3.94 ± 18.23 | 3.08 ± 23.43 |
| Cycle 18 Day 15 | 5.80 ± 22.59 | 4.99 ± 25.32 |
| Cycle 19 Day 15 | 3.94 ± 18.56 | 0.77 ± 26.40 |
| Cycle 20 Day 15 | 6.50 ± 16.94 | -0.25 ± 27.78 |
| Cycle 21 Day 15 | 6.54 ± 17.38 | 4.09 ± 25.89 |
| Cycle 22 Day 15 | 7.73 ± 17.19 | 1.04 ± 25.30 |
| Cycle 23 Day 15 | 4.94 ± 17.10 | 0.79 ± 23.80 |
| Cycle 24 Day 15 | 9.65 ± 22.25 | 6.28 ± 26.34 |
| Cycle 25 Day 15 | 7.89 ± 22.99 | 1.67 ± 28.68 |
| Cycle 26 Day 15 | 8.33 ± 23.68 | -3.09 ± 29.96 |
| Cycle 27 Day 15 | 8.33 ± 23.33 | 11.97 ± 28.50 |
| Cycle 28 Day 15 | 14.07 ± 28.32 | 3.70 ± 23.57 |
| Cycle 29 Day 15 | 7.94 ± 21.09 | -1.11 ± 21.24 |
| Cycle 30 Day 15 | 12.04 ± 28.21 | 6.35 ± 15.53 |
| EOT | -3.41 ± 22.56 | -1.91 ± 24.90 |
The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for body image and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 3.24 ± 25.33 | 2.59 ± 26.55 |
| Cycle 3 Day 15 | 1.88 ± 26.50 | 1.55 ± 23.59 |
| Cycle 4 Day 15 | 0.88 ± 24.25 | 4.76 ± 25.24 |
| Cycle 5 Day 15 | -0.61 ± 27.17 | 2.90 ± 24.83 |
| Cycle 6 Day 15 | -0.91 ± 25.65 | 5.78 ± 26.40 |
| Cycle 7 Day 15 | -1.17 ± 28.09 | 4.20 ± 25.60 |
| Cycle 8 Day 15 | -1.00 ± 25.93 | 3.76 ± 22.72 |
| Cycle 9 Day 15 | 1.55 ± 25.30 | 5.17 ± 24.32 |
| Cycle 10 Day 15 | -0.55 ± 25.45 | 3.58 ± 26.11 |
| Cycle 11 Day 15 | -3.58 ± 23.88 | 1.72 ± 23.61 |
| Cycle 12 Day 15 | -1.25 ± 24.20 | 0.89 ± 23.87 |
| Cycle 13 Day 15 | -3.24 ± 28.21 | 2.72 ± 25.18 |
| Cycle 14 Day 15 | -3.70 ± 29.31 | 1.92 ± 24.94 |
| Cycle 15 Day 15 | -4.17 ± 30.30 | 4.38 ± 23.16 |
| Cycle 16 Day 15 | -1.57 ± 29.05 | 0.00 ± 25.20 |
| Cycle 17 Day 15 | -2.53 ± 26.57 | -2.41 ± 24.85 |
| Cycle 18 Day 15 | -1.00 ± 28.41 | 1.45 ± 25.84 |
| Cycle 19 Day 15 | -2.15 ± 27.57 | -1.15 ± 26.47 |
| Cycle 20 Day 15 | 2.52 ± 28.38 | -3.70 ± 27.73 |
| Cycle 21 Day 15 | -3.27 ± 34.80 | 1.75 ± 21.85 |
| Cycle 22 Day 15 | 1.45 ± 29.78 | 5.21 ± 24.11 |
| Cycle 23 Day 15 | -1.85 ± 29.76 | 1.19 ± 23.10 |
| Cycle 24 Day 15 | 2.63 ± 36.66 | 7.25 ± 22.38 |
| Cycle 25 Day 15 | 1.08 ± 34.94 | 3.33 ± 18.42 |
| Cycle 26 Day 15 | 6.94 ± 36.75 | 9.26 ± 25.06 |
| Cycle 27 Day 15 | 13.33 ± 34.88 | 7.69 ± 19.97 |
| Cycle 28 Day 15 | 6.67 ± 28.73 | 0.00 ± 16.67 |
| Cycle 29 Day 15 | 4.76 ± 36.65 | 3.33 ± 18.92 |
| Cycle 30 Day 15 | 13.89 ± 30.01 | 9.52 ± 16.27 |
| EOT | -4.92 ± 27.93 | 0.67 ± 27.35 |
The EQ-5D-5L is a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and a VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The VAS records the respondent's self-rated health on a 20-cm vertical scale ranging from 0: the worst health you can imagine to 100: the best health you can imagine. Change from baseline in VAS is reported here. A higher score in VAS and positive change from baseline represents a better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.
| score on a scale | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| Cycle 2 Day 1 | 0.99 ± 17.62 | -0.39 ± 14.58 |
| Cycle 3 Day 15 | -0.52 ± 17.35 | -0.10 ± 16.28 |
| Cycle 4 Day 15 | 0.75 ± 18.66 | -0.24 ± 19.36 |
| Cycle 5 Day 15 | 0.09 ± 17.78 | 1.03 ± 19.20 |
| Cycle 6 Day 15 | 0.50 ± 19.54 | 2.39 ± 18.17 |
| Cycle 7 Day 15 | -1.55 ± 20.69 | 3.02 ± 18.01 |
| Cycle 8 Day 15 | 0.12 ± 17.97 | -0.14 ± 18.03 |
| Cycle 9 Day 15 | 0.87 ± 19.39 | 0.62 ± 16.07 |
| Cycle 10 Day 15 | 2.65 ± 15.86 | 2.38 ± 15.85 |
| Cycle 11 Day 15 | -0.51 ± 20.30 | -1.66 ± 17.53 |
| Cycle 12 Day 15 | 1.97 ± 20.67 | -0.51 ± 17.55 |
| Cycle 13 Day 15 | 2.83 ± 18.71 | 3.41 ± 15.74 |
| Cycle 14 Day 15 | 1.58 ± 18.62 | -0.83 ± 17.36 |
| Cycle 15 Day 15 | 2.41 ± 20.90 | -1.69 ± 17.75 |
| Cycle 16 Day 15 | 2.38 ± 20.48 | 0.72 ± 19.44 |
| Cycle 17 Day 15 | 2.90 ± 18.33 | -0.13 ± 17.38 |
| Cycle 18 Day 15 | 3.45 ± 15.70 | 0.53 ± 23.17 |
| Cycle 19 Day 15 | -0.05 ± 18.17 | -6.00 ± 15.16 |
| Cycle 20 Day 15 | -2.14 ± 12.24 | -2.92 ± 21.34 |
| Cycle 21 Day 15 | -5.20 ± 24.93 | 1.88 ± 9.19 |
| EOT visit | -4.25 ± 21.94 | -5.17 ± 17.11 |
BM aspirate was collected for fluorescent in situ hybridization for analysis of del\[17p\], t\[4;14\], t\[14;16\]) and 1q21+. ORR was also evaluated based on IRC assessment by disease characteristics. ORR for participants with at least 1 chromosomal abnormality i.e. \[del(17p)\] or \[1q21+ and t(4;14) or t(14;16)\] is presented. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| ORR Based on at Least 1 Chromosomal Abnormality | 62.3 | 62.5 |
Collected over Adverse events and deaths were collected from first dose of study medication administration (Day 1) up to 30 days after the last dose of study medication, approximately 38 months. Partial results are presented up to DCO date of 29-Aug-2025.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Isa-IV + Pd | 73/268 (27.2%) | 152/264 (57.6%) | 248/264 (93.9%) |
| Isa-SC + Pd | 77/263 (29.3%) | 160/263 (60.8%) | 242/263 (92%) |
| Event | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| PneumoniaInfections and infestations | 48/264 | 54/263 |
| Covid-19Infections and infestations | 7/264 | 11/263 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 5/264 | 9/263 |
| Platelet Count DecreasedInvestigations | 9/264 | 4/263 |
| Acute Kidney InjuryRenal and urinary disorders | 2/264 | 8/263 |
| Covid-19 PneumoniaInfections and infestations | 6/264 | 7/263 |
| AnaemiaBlood and lymphatic system disorders | 4/264 | 6/263 |
| InfluenzaInfections and infestations | 6/264 | 4/263 |
| Pneumonia InfluenzalInfections and infestations | 6/264 | 5/263 |
| Disease ProgressionGeneral disorders | 6/264 | 4/263 |
| Event | Isa-IV + Pd | Isa-SC + Pd |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 88/264 | 93/263 |
| Upper Respiratory Tract InfectionInfections and infestations | 76/264 | 74/263 |
| DiarrhoeaGastrointestinal disorders | 67/264 | 60/263 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 63/264 | 6/263 |
| FatigueGeneral disorders | 43/264 | 57/263 |
| Neutrophil Count DecreasedInvestigations | 41/264 | 48/263 |
| InsomniaPsychiatric disorders | 42/264 | 46/263 |
| ConstipationGastrointestinal disorders | 39/264 | 39/263 |
| Oedema PeripheralGeneral disorders | 38/264 | 33/263 |
| Covid-19Infections and infestations | 36/264 | 32/263 |
Baseline characteristics were assessed for all randomized population.
| Age, Continuous(years) | Isa-IV + Pd | Isa-SC + Pd | Total |
|---|---|---|---|
| Mean | 64.7 ± 9.7 | 65.7 ± 9.4 | 65.2 ± 9.6 |
| Sex: Female, Male(Participants) | Isa-IV + Pd | Isa-SC + Pd | Total |
|---|---|---|---|
| Female | 112 | 126 | 238 |
| Male | 156 | 137 | 293 |
| Race (NIH/OMB)(Participants) | Isa-IV + Pd | Isa-SC + Pd | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 58 | 53 | 111 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 14 | 8 | 22 |
| White | 184 | 184 | 368 |
| More than one race | 0 | 3 | 3 |
| Unknown or Not Reported | 11 | 14 | 25 |
Showing the first 100 of 128 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.
Ran from Jun 2022 to primary completion in Nov 2024, 28 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 28 months is below that.
Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab